Document:

Security Agreement

  
 Exhibit 10.3

  
 Execution Copy 
  
 SECURITY AGREEMENT 
  
 DATED NOVEMBER 9, 2004 
  
 FROM 
  
 THE GRANTOR REFERRED TO HEREIN 
  
 AS GRANTOR 
  
 TO 
  
 U.S.
BANK NATIONAL ASSOCIATION 
  
 AS COLLATERAL AGENT

  
 TABLE OF CONTENTS

  

			
	 SECTION

	  	PAGE

		
	 Section 1. Grant of Security
	  	2
		
	 Section 2. Security for Obligations
	  	7
		
	 Section 3. Grantor Remains Liable
	  	7
		
	 Section 4. Product Deposit Account
	  	7
		
	 Section 5. Representations and Warranties
	  	8
		
	 Section 6. Further Assurances
	  	12
		
	 Section 7. As to Product Equipment and Product Inventory
	  	14
		
	 Section 8. Insurance
	  	14
		
	 Section 9. Post-Closing Changes; Bailees; Collections on Product IP Agreements, Product Agreements, and Assigned Agreements;
NDAs
	  	15
		
	 Section 10. As to Intellectual Property Collateral
	  	17
		
	 Section 11. As to the Product IP Agreements, Product Agreements and Assigned Agreements
	  	19
		
	 Section 12. Payments Under the Product IP Agreements, Product Agreements and Assigned Agreements
	  	20
		
	 Section 13. Transfers and Other Liens
	  	20
		
	 Section 14. Collateral Agent Appointed Attorney-in-Fact
	  	20
		
	 Section 15. Collateral Agent May Perform
	  	21
		
	 Section 16. The Collateral Agent’s Duties
	  	21
		
	 Section 17. Remedies
	  	22
		
	 Section 18. Indemnity and Expenses
	  	24
		
	 Section 19. Amendments; Waivers
	  	24
		
	 Section 20. Notices, Etc.
	  	24
		
	 Section 21. Continuing Security Interest
	  	25

  

			
		
	 Section 22. Release; Termination
	  	25
		
	 Section 23. Security Interest Absolute
	  	26
		
	 Section 24. Execution in Counterparts
	  	27
		
	 Section 25. Governing Law
	  	27
		
	 Section 26. Jurisdiction, Etc.
	  	27
		
	 Section 27. WAIVER OF JURY TRIAL
	  	27

  

 ii 

			
	 SCHEDULES
	  	 
		
	 Schedule I
	  	Chief Executive Office, Type Of Organization, Jurisdiction Of Organization And Organizational Identification Number
		
	 Schedule II
	  	Product Agreements and Assigned Agreements
		
	 Schedule III
	  	Descriptions and Locations of Product Equipment and Product Inventory
		
	 Schedule IV
	  	Changes in Name, Location, Etc.
		
	 Schedule V
	  	Intellectual Property: Product Patents, Product Trademarks, Domain Names, Trade Dress, Product Trade Secrets, Product Copyrights and Product IP Agreements
		
	 Schedule VI
	  	Books and Records
		
	 Schedule VII
	  	New Drug Applications & Investigational New Drug Applications
		
	 Schedule VIII
	  	Product Deposit Account
		
	 Schedule IX
	  	Commercial Tort Claims
		
	 EXHIBITS
	  	 
		
	 Exhibit A
	  	Form of Intellectual Property Security Agreement
		
	 Exhibit B
	  	Form of Intellectual Property Security Agreement Supplement
		
	 Exhibit C
	  	Form of NDA Transfer Letter
		
	 Exhibit D
	  	Form of Deposit Account Control Agreement

  

 iii 

  
 SECURITY AGREEMENT

  
 SECURITY AGREEMENT (this
“Agreement”) dated as of November 9, 2004 made by and between VIROPHARMA INCORPORATED, a Delaware corporation (the “Grantor”), and U.S. BANK NATIONAL ASSOCIATION, as collateral agent (in such capacity,
together with any successor collateral agent, the “Collateral Agent”) for the Secured Parties (as defined herein). 
  
 PRELIMINARY STATEMENTS 
  
 (1) The Grantor has entered into an Indenture dated as of October 18, 2004 (as it may hereafter be amended, amended and restated, supplemented or
otherwise modified from time to time, the “Bridge Indenture”) with U.S. Bank National Association, as Trustee (in such capacity, the “Trustee”), pursuant to which the Grantor has authorized the
issuance of 10% Senior Secured Bridge Notes due 2005 (as they may hereafter be amended, amended and restated, supplemented or otherwise modified from time to time, the “Bridge Notes”). 
  
 (2) Upon the fulfillment of certain conditions set forth in the Bridge
Indenture, the Bridge Notes shall automatically be exchanged for Grantor’s 6% Convertible Senior Secured Notes due 2009 (as they may hereafter be amended, amended and restated, supplemented, or otherwise modified from time to time, the
“2009 Notes,” and together with the Bridge Notes, collectively, the “Notes”) issued pursuant to an Indenture entered into between Grantor and Trustee, dated as of October 18, 2004 (as it may hereafter
be amended, amended and restated, supplemented, or otherwise modified from time to time, the “2009 Indenture,” and together with the Bridge Indenture, each an “Indenture” and collectively the
“Indentures”); 
  
 (3) The Grantor and Eli
Lilly and Company, an Indiana corporation (“Lilly”), have entered into an Assignment, Transfer and Assumption Agreement, dated as of October 18, 2004 (the “Transfer Agreement”), pursuant to which Lilly
has agreed, among others, to sell or license, and the Grantor has agreed, among others, to purchase or receive a license in, certain assets (the “Purchased Assets”); 
  
 (4) Pursuant to the Indenture in effect from time to time, the Grantor is
entering into this Agreement in order to grant to the Collateral Agent for the ratable benefit of the Collateral Agent, the Trustee and the holders of the Notes (the “Holders”, and together with the Collateral Agent and the
Trustee, collectively, the “Secured Parties”) a security interest in the Purchased Assets. 
  
 (5) The Grantor will derive substantial direct and indirect benefit from the transactions contemplated by the Indentures and the Notes issued thereunder.

  
 (6) Terms defined in the Indenture then in effect and not
otherwise defined in this Agreement are used in this Agreement as defined in such Indenture. Further, unless otherwise defined in this Agreement or in the Indentures, terms defined in Article 9 of the UCC (as defined below) are used in this
Agreement as such terms are defined in such Article 9. “UCC” means the Uniform Commercial Code as in effect, from time to time, in the State of New York; provided that, if perfection or the effect of perfection or
non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a 

 
jurisdiction other than the State of New York, “UCC” means the Uniform Commercial Code as in effect from time to time in such other
jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority. 
  
 NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Grantor hereby agrees with the Collateral Agent for the ratable benefit of the Secured Parties as follows: 
  
 Section 1. Grant of Security. The Grantor hereby grants to the Collateral Agent, for the ratable benefit of the Secured Parties, a security
interest in the Grantor’s right, title and interest in and to the following, in each case, as to each type of property described below, whether now owned or hereafter acquired by the Grantor, wherever located, and whether now or hereafter
existing or arising (collectively, the “Collateral”): 
  
 (a) all right, title and interest of the Grantor in and to all United States new drug applications and investigational new drug applications filed with the United States Food and Drug Administration
(“FDA”) and listed on Schedule VII hereto and all other submissions, supplements or amendments pertaining thereto, (the “Marketed Product NDAs”), with respect to Vancomycin (vancomycin hydrochloride),
as marketed as of the date hereof in the Territory (as defined herein) as Vancocin® under NDA No. 50-606 and any other pharmaceutical products listed therein as may be marketed as of the date hereof in the Territory (the “Marketed Product”), including, without
limitation, the materials contained in the official Marketed Product NDA files, including all Marketed Product NDA submissions, amendments, supplements, correspondence (including correspondence with the FDA field offices, FDA laboratories, FDA
compliance offices and DDMAC), reports and memoranda of telephone conversations, constituting or reflecting communications between Lilly and the FDA regarding the Marketed Product NDA, such material in the working regulatory and clinical files
pertaining to the conduct of upcoming annual reviews of the Marketed Product and required reports to the FDA that have yet to be filed, in each of the foregoing cases, which are purchased by the Grantor from Lilly pursuant to the Transfer Agreement,
other than (i) primary sources such as laboratory notebooks or historical records not relevant to the maintenance of regulatory filings relating to the Marketed Product and marketing authorizations and (ii) any other submissions, supplements or
amendments, files or data pertaining solely to jurisdictions outside the fifty (50) states and the District of Columbia and any territories or commonwealths constituting the United States of America, including Puerto Rico (the
“Territory”); 
  
 (b) all
right, title and interest of the Grantor in and to all United States new drug applications, abbreviated new drug applications and investigational new drug applications filed with the FDA and listed on Schedule VII hereto, and all other submissions,
supplements or amendments pertaining thereto (the “Discontinued Product ANDAs”, and collectively with the Marketed Product NDAs, the “NDAs”), with respect to the pharmaceutical products listed therein
as may be marketed after the date hereof in the Territory (the “Discontinued Product”, and together with the Marketed Product, the “Product”), in each of the foregoing cases, which are purchased by the
Grantor from Lilly pursuant to the Transfer Agreement, other than (i) primary sources such as laboratory notebooks or historical records not relevant to the maintenance of regulatory filings relating to the Discontinued Product and marketing 

  

 -2- 

 
authorizations and (ii) any other submissions, supplements or amendments, files or data pertaining solely to jurisdictions outside of the Territory;

  
 (c) all of the Grantor’s right, title
and interest in and to all equipment and machinery located within the Territory which is now or hereafter owned by the Grantor and primarily used by or on behalf of the Grantor for the manufacture, production, preparation, packaging or shipment of
the Product in the Territory (collectively, the “Product Equipment”), in all of its forms, including, without limitation, all parts thereof and all accessions thereto and all software related thereto, including, without
limitation, to the extent permitted by applicable law, software that is embedded in and is part of the Product Equipment; 
  
 (d) all of the Grantor’s right, title and interest in and to all inventory located within the Territory which are used or consumed
in, or result from, the manufacture, production, preparation or shipping of the Product by or on behalf of the Grantor, in all of its forms, including, without limitation, (i) all raw materials, work in process, finished goods and materials used or
consumed in the manufacture, production, preparation or shipping of the Product, (ii) Product or components thereof in which the Grantor has an interest in mass or a joint or other interest or right of any kind (including, without limitation, those
in which the Grantor has an interest or right as consignee) and (iii) the Product or components thereof that are returned to or repossessed or stopped in transit by the Grantor, and all accessions thereto and products thereof and documents therefor,
and all software related thereto (any and all such property being the “Product Inventory”); 
  
 (e) all of the Grantor’s right, title and interest in and to all accounts, instruments (including, without limitation, promissory
notes), general intangibles (including, without limitation, payment intangibles) and other obligations of any kind from obligors who maintain their chief executive office inside of the Territory or are organized under laws of a jurisdiction within
the Territory in respect of the Product, whether or not arising out of or in connection with the sale or lease of such Product, or the rendering of services and whether or not earned by performance, and all rights now or hereafter existing in and to
all supporting obligations, security agreements, mortgages, Liens (as defined herein), letters of credit and other contracts securing or otherwise relating to the foregoing (any and all of such accounts, instruments, general intangibles and other
obligations, to the extent not referred to in clause (h) below, being the “Product Receivables”, and any and all such supporting obligations, security agreements, mortgages, Liens, letters of credit and other contracts being
the “Product Receivables Agreements”); 
  
 (f) all of the Grantor’s right title and interest in and to all manufacturing agreements, transition services agreements, leases and other agreements (but excluding the Assigned Agreements and the Product IP
Agreements (each as defined below) and, to the extent not prohibited by applicable law (taking into account the provisions of 9-406, 9-407, 9-408 or 9-409 of the UCC), all agreements with an agency, department or instrumentality of the United States
of America or any state governmental authority in the United States of America) to which the Grantor is now or may hereafter become a party or beneficiary, including without limitation those “Product Agreements” listed in Schedule II
hereto, and which primarily relate to the manufacture, production, shipment, marketing, sale, or distribution of the Product in the Territory, in each case, as such agreements may be amended, amended and restated, 

  

 -3- 

 
supplemented or otherwise modified from time to time (collectively, the “Product Agreements”) and including, without limitation, (i)
all rights of the Grantor to receive moneys due and to become due under or pursuant to the Product Agreements, (ii) all rights of the Grantor to receive proceeds of any insurance, indemnity, warranty or guaranty with respect to the Product
Agreements, (iii) claims of the Grantor for damages arising out of or for breach of or default under the Product Agreements and (iv) the right of the Grantor to terminate the Product Agreements, to perform thereunder and to compel performance and
otherwise exercise all remedies thereunder (all such Collateral being the “Product Agreement Collateral”); 
  
 (g) all of the Grantor’s right, title and interest in and to each of the agreements listed in Schedule II hereto as the
“Assigned Agreements” which are assigned to the Grantor by Lilly pursuant to the Transfer Agreement, in each case as such agreements may be amended, amended and restated, supplemented or otherwise modified from time to time (collectively,
the “Assigned Agreements”) and including, without limitation, (i) all rights of the Grantor to receive moneys due and to become due under or pursuant to the Assigned Agreements, (ii) all rights of the Grantor to receive
proceeds of any insurance, indemnity, warranty or guaranty with respect to the Assigned Agreements, (iii) claims of the Grantor for damages arising out of or for breach of or default under the Assigned Agreements and (iv) the right of the Grantor to
terminate the Assigned Agreements, to perform thereunder and to compel performance and otherwise exercise all remedies thereunder (all such Collateral being the “Assigned Agreement Collateral”); 
  
 (h) all of the Grantor’s right, title and interest in
and to the Product Deposit Account (defined below) and all interest, dividends, distributions, cash, instruments and other property from time to time received, receivable or otherwise distributed in connection therewith (collectively, the
“Account Collateral”); 
  
 (i) the following (collectively, the “Product Intellectual Property Collateral”): 
  
 (i) all of the Grantor’s right, title and interest in and to all, (i) patents, patent applications, utility models and statutory
invention registrations, together with all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations thereof, in the Territory and listed in Schedule V hereto, all inventions claimed or disclosed therein and
all improvements thereto (the “Purchased Patents”) and (ii) all patents, patent applications, utility models and statutory invention registrations, together with all reissues, divisions, continuations, continuations-in-part,
extensions, renewals and reexaminations thereof, now or hereafter owned by the Grantor in the Territory and which primarily relate to the manufacture, production, shipment, marketing, sale or distribution of the Product in the Territory (the
“Future Product Patents,” and collectively with the Purchased Patents, the “Product Patents”); 
  
 (ii) all of the Grantor’s right, title and interest in and to all (i) trademarks listed in Schedule V hereto in the Territory,
together, in each case, with the goodwill symbolized thereby (the “Purchased Trademarks”), and (ii) all trademarks, service marks, domain names, common law trade dress rights in the appearance, look, shape, size or color of
the Product, logos, designs, slogans, and 

  

 -4- 

 
other source identifiers, whether registered or unregistered, which are now or hereafter owned by the Grantor in the Territory and which are primarily used
by the Grantor in the marketing, sale and distribution of the Product in the Territory, together, in each case, with the goodwill symbolized thereby (the “Future Product Trademarks,” and collectively with the Purchased
Trademarks, the “Product Trademarks”); provided that, (x) no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a
security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law and (y) no security interest is granted in and to any trademark, service mark, domain name, common law
trade dress right, logo, design and slogan and other source identifier which is of general applicability to the Grantor or the Grantor’s corporate identity generally or that pertain to products or services of the Grantor other than or in
addition to the Product including, without limitation, those identified in Part VII of Schedule V hereto; 
  
 (iii) all of the Grantor’s right, title and interest in and to all copyrights listed in Schedule V hereto in the Territory (the
“Purchased Copyrights”) and to all copyrights in the Territory in and to (A) all materials comprising the NDAs in any media, (B) all materials comprising the books and records listed in Schedule VI hereto and (C) all
materials comprising the Product Marketing Materials (as defined below), including, without limitation, those copyrights set forth in Schedule V hereto (the “Product Copyrights”); 
  
 (iv) all of the Grantor’s right, title and interest in
and to all confidential and proprietary information, including, without limitation, know-how, including, without limitation, specifications, tangible or intangible manufacturing technology and processes, physical chemistry and formulation technology
and processes, analytical testing and validation technology and processes, technical knowledge, tangible or intangible trade secrets, production processes and techniques, data and results, chemical samples or substances, inventions, research and
development information, sources of supply, manufacturing, packaging and other equipment, including the design thereof, and all other factual knowledge, whether patentable or unpatentable, in each case, which are now or hereafter owned by the
Grantor and primarily used by the Grantor in the manufacture, packaging, marketing, distribution, promotion, co-marketing, co-promoting, sale, offers for sale, use and importation of the Product in the Territory (collectively, the
“Product Trade Secrets”); 
  
 (v) all of the Grantor’s right, title and interest in and to all market research, marketing plans, media plans, advertising, marketing-related clinical study results, form letters and medical queries, sales training materials, customer
lists (including doctors, general purchasing organizations and pharmacists), promotional and marketing books and records, promotional and informational materials, including flyers, brochures, pamphlets, package inserts, product samples, medical
education slides, monographs or CME program video cassettes, computer disks, CD-ROMs, websites, non-licensed software, tradeshow materials 

  

 -5- 

 
and booths, literature, journal articles or reprints, sales or other manuals or any similar materials or items, and advertising, in each case, which are now
or hereafter owned by the Grantor in the Territory and primarily used by the Grantor in the marketing and promotion of the Products in the Territory (collectively, the “Product Marketing Materials”); 
  
 (vi) all registrations and applications for registration for
any of the foregoing, including, without limitation, those registrations and applications for registration set forth in Schedule V hereto (as such Schedule V may be supplemented from time to time by supplements to this Agreement, each such
supplement being substantially in the form of Exhibit B hereto (an “IP Security Agreement Supplement”) executed by the Grantor and delivered to the Collateral Agent from time to time), together with all reissues, divisions,
continuations, continuations-in-part, extensions, renewals and reexaminations thereof; 
  
 (vii) all of the Grantor’s right, title and interest in and to all tangible embodiments of the foregoing and all other rights of any
kind whatsoever of the Grantor accruing thereunder or pertaining thereto; 
  
 (viii) all of the Grantor’s right, title and interest in and to all agreements, permits, consents, orders, license agreements, sublicense agreements and franchises to which the Grantor, now or hereafter, is a
party or a beneficiary, and which primarily relate to the license, sublicense, development, use or disclosure of any property not owned by the Grantor but is otherwise of any type described in clauses (i) through (vii) above and primarily used by
the Grantor in the manufacture, production, shipment, marketing, sale or distribution of the Product in the Territory including, without limitation, the agreements set forth in Schedule V hereto, in each case to the extent permitted by applicable
law (the “Product IP Agreements”) and including, without limitation, (i) all rights of the Grantor to receive moneys due and to become due under or pursuant to the Product IP Agreements, (ii) all rights of the Grantor to
receive proceeds of any insurance, indemnity, warranty or guaranty with respect to the Product IP Agreements, (iii) claims of the Grantor for damages arising out of or for breach of or default under the Product IP Agreements and (iv) the right of
the Grantor to terminate the Product IP Agreements, to perform thereunder and to compel performance and otherwise exercise all remedies thereunder (all such Collateral being the “Product IP Agreement Collateral”); and

  
 (ix) all of the Grantor’s right, title
and interest in and to any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the
obligation, to sue for and collect, or otherwise recover, such damages; 
  
 (j) all of the Grantor’s right, title and interest in and to books and records (including, without limitation, customer lists, credit files, printouts and other computer output materials and records) of the
Grantor as set forth in Schedule VI hereto which primarily relate to 

  

 -6- 

 
the Grantor’s manufacture, production, shipment, marketing, sale or distribution of the Product in the Territory; 
  
 (k) all of the Grantor’s right, title and interest in
and to (i) all other property, rights or assets which constitute the Purchased Assets within the meaning of the Transfer Agreement and (ii) all other licenses received by the Grantor as set forth in the Transfer Agreement; and 
  
 (l) all proceeds (including, without limitation, cash) of,
collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the foregoing (including, without limitation, proceeds, collateral and supporting
obligations that constitute property of the types described in clauses (a) through (k) of this Section 1 and this clause (l)) and, to the extent not otherwise included, all (A) payments under insurance (whether or not the Collateral Agent is the
loss payee thereof), or any indemnity, warranty or guaranty, payable by reason of loss or damage to or otherwise with respect to any of the foregoing Collateral, and (B) commercial tort claims described on Schedule IX hereto with respect to any of
the foregoing Collateral. 
  
 Section 2. Security for
Obligations. This Agreement secures the payment of all obligations of the Grantor now or hereafter existing under the Bridge Indenture, the Bridge Notes, the 2009 Indenture and the 2009 Notes, in each case, whether direct or indirect,
absolute or contingent, and whether for principal, reimbursement obligations, interest, fees, premiums, penalties, indemnifications, contract causes of action, costs, expenses or otherwise (all such obligations being the “Secured
Obligations”). 
  
 Section 3. Grantor Remains
Liable. Anything herein to the contrary notwithstanding, (a) the Grantor shall remain liable under the contracts and agreements included in the Grantor’s Collateral to the extent set forth therein to perform all of its duties and
obligations thereunder to the same extent as if this Agreement had not been executed, (b) the exercise by the Collateral Agent of any of the rights hereunder shall not release the Grantor from any of its duties or obligations under the contracts and
agreements included in the Collateral and (c) prior to the exercise of the Secured Parties’ rights under this Agreement, no Secured Party shall have any obligation or liability under the contracts and agreements included in the Collateral by
reason of this Agreement, the Indentures or the Notes, nor shall any Secured Party be obligated to perform any of the obligations or duties of the Grantor thereunder or to take any action to collect or enforce any claim for payment assigned
hereunder. 
  
 Section 4. Product Deposit Account.

  
 (a) The Grantor shall: (i) on or prior to the
date of this Agreement, open a lockbox deposit account (such account, together with any other account set forth on Schedule VIII as amended under the terms of Section 4(c) hereof, collectively, the “Product Deposit Account”)
with a financial institution selected in its sole discretion (the “Pledged Account Bank”); and (ii) within 20 days after the date of this Agreement, deliver to the Collateral Agent a Deposit Account Control Agreement
substantially in the form of Exhibit D hereto, or otherwise in form and substance reasonably satisfactory to the Collateral Agent (the “Deposit Account  

  

 -7- 

 
Control Agreement”), authenticated by the Grantor, the Collateral Agent and the Pledged Account Bank. 
  
 (b) On and after the establishment of the Product Deposit
Account, the Grantor covenants and agrees, so long as any Secured Obligation of the Grantor under the Indentures shall remain unpaid or be outstanding: (i) to instruct each Person obligated at any time to make any payment to the Grantor in respect
of any Product Receivable to make such payment to the Product Deposit Account; (ii) to deposit all amounts it shall otherwise receive as payment in connection with any Product Receivable into the Product Deposit Account and (iii) not to instruct any
Person obligated at any time to make any payment to the Grantor in respect of any Product Receivable to make such payment to any account other than the Product Deposit Account. 
  
 (c) The Grantor agrees that (i) so long as no Event of Default shall have occurred and be continuing, it
will not open any new Product Deposit Account unless (A) the Collateral Agent shall have received at least 10 days’ prior written notice of such new Product Deposit Account, (B) the Collateral Agent shall have received promptly thereafter an
amended Schedule VIII hereto which reflects such additional Product Deposit Account and (C) within 20 days after such new Product Deposit Account shall have been opened, the Collateral Agent shall have received a Deposit Account Control Agreement
authenticated by the Grantor, the Collateral Agent and the Pledged Account Bank and (ii) at any time following the occurrence and during the continuance of an Event of Default, it will not open any new Product Deposit Account other than as requested
by the Collateral Agent or as required under this Agreement and provided that (A) the Collateral Agent shall have received, in the case of a Pledged Account Bank that is not the Collateral Agent, a Deposit Account Control Agreement authenticated by
such new bank and Grantor, or a supplement to an existing Deposit Account Control Agreement with such then existing Pledged Account Bank, covering such new Product Deposit Account and (B) the Collateral Agent shall have received promptly thereafter
an amended Schedule VIII hereto which reflects such additional Product Deposit Account subject to a Deposit Account Control Agreement. The Grantor agrees that it will not at any time terminate any bank as a Pledged Account Bank or terminate any
Product Deposit Account unless Grantor gives the Collateral Agent at least 10 days’ prior written notice of such termination (and, upon such termination, the Grantor shall deliver an amended Schedule VIII which reflects the deletion of such
Product Deposit Account). 
  
 (d) Upon any
termination by the Grantor of any Product Deposit Account pursuant to and in accordance with Section 4(c), the Grantor will immediately transfer all funds and property held in such terminated Product Deposit Account to another account listed on
Schedule VIII and notify all obligors that were making payments with respect to Product Receivables to cease making payments to such terminated Product Deposit Account and to make all future payments to another Product Deposit Account listed on
Schedule VIII hereto. 
  
 Section 5. Representations and
Warranties. The Grantor represents and warrants that as of the date hereof: 
  
 (a) The Grantor’s exact legal name, as defined in Section 9-503(a) of the UCC, is correctly set forth in Schedule I hereto. The
Grantor is located (within the meaning of 

  

 -8- 

 
Section 9-307 of the UCC) and has its chief executive office in the state or jurisdiction set forth in Schedule I hereto. The information set forth in
Schedule I hereto with respect to the Grantor is true and accurate in all respects. The Grantor has not previously changed its name, location of its chief executive office, type of organization, jurisdiction of organization or organizational
identification number from those set forth in Schedule I hereto except as disclosed in Schedule IV hereto. 
  
 (b) All of the Product Equipment and Product Inventory of the Grantor are located at the places specified therefor in Schedule III hereto,
as such Schedule III may be amended from time to time pursuant to Section 7(a). Executed copies of each Product IP Agreement and each Product Agreement and Assigned Agreement listed in Schedule II hereto have been delivered to the Collateral Agent.
None of the Product Receivables, Product IP Agreement Collateral, Product Agreement Collateral or Assigned Agreement Collateral is evidenced by a promissory note or other instrument that has not been delivered to the Collateral Agent. 
  
 (c) The Grantor is the legal and beneficial owner of the
Collateral, free and clear of any lien, security interest, pledge, or hypothecation (collectively, “Liens”, and each individually, a “Lien”), except for the security interest created under this
Agreement and Permitted Encumbrances (as defined in the Transfer Agreement). No effective financing statement or other instrument similar in effect covering all or any part of such Collateral is on file in any recording or filing office, except such
as may have been filed in favor of the Collateral Agent relating to the Indentures, the Notes and this Agreement. 
  
 (d) The Grantor has exclusive possession and control of the Product Equipment and Product Inventory other than the Product Equipment or
Product Inventory stored at any leased premises or warehouse for which a landlord’s or warehouseman’s agreement, in form and substance satisfactory to the Collateral Agent, is in effect and which leased premises or warehouse is so
indicated by an asterisk on Schedule III hereto, as such Schedule III may be amended from time to time pursuant to Section 7(a). In the case of Product Equipment and Product Inventory located on leased premises or in warehouses, no lessor or
warehouseman of any premises or warehouse upon or in which such Product Equipment and Product Inventory is located has (i) issued any warehouse receipt or other receipt in the nature of a warehouse receipt in respect of any Product Equipment and
Product Inventory, (ii) issued any document for any of the Grantor’s Product Equipment and Product Inventory, (iii) received notification of any secured party’s interest (other than the security interest granted hereunder) in the
Grantor’s Product Equipment and Product Inventory or (iv) any Lien, claim or charge (based on contract, statute or otherwise) on such Product Equipment and Product Inventory. 
  
 (e) To the best of Grantor’s knowledge, the Product IP Agreements, Product Agreements and Assigned
Agreements to which the Grantor is a party, true and complete and executed copies of which have been furnished to the Collateral Agent, have been duly authorized, executed and delivered by all parties thereto, have not been amended, amended and
restated, supplemented or otherwise modified, are in full force and effect and are binding upon and enforceable against all parties thereto in accordance with their terms, except as such enforceability may be limited by general principles of equity
or applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium, liquidation or similar laws 

  

 -9- 

 
relating to, or affecting generally, the enforcement of creditors’ rights and remedies. To the best of Grantor’s knowledge, there exists no default
under any Product IP Agreement, Product Agreement or Assigned Agreement to which the Grantor is a party by any party thereto. 
  
 (f) Except for the filings of the Intellectual Property Security Agreement with the U.S. Patent and Trademark Office and the U.S.
Copyright Office, all filings and other actions necessary to perfect the security interest in the Collateral of the Grantor created under this Agreement have been duly made or taken and are in full force and effect, and this Agreement creates in
favor of the Collateral Agent for the benefit of the Secured Parties a valid and, together with such filings and other actions, perfected first priority security interest in the Collateral of the Grantor, securing the payment of the Secured
Obligations. 
  
 (g) No authorization or approval
or other action by, and no notice to or filing with, any governmental authority or regulatory body or any other third party is required for (i) the grant by the Grantor of the security interest granted hereunder or for the execution, delivery or
performance of this Agreement by the Grantor and (ii) the perfection or maintenance of the security interest created hereunder (including the first priority nature of such security interest), except for the filing of financing and continuation
statements under the UCC, which financing statements have been duly filed and are in full force and effect and the recordation of the Intellectual Property Security Agreements referred to in Section 10(e) with the U.S. Patent and Trademark Office
and the U.S. Copyright Office, which Agreements will, within 90 days of the date of this Agreement, be duly recorded and in full force and effect upon the acceptance of such recordations. 
  
 (h) The Grantor has no other deposit accounts in or to which
payments in respect of the Product Receivables will be deposited or credited, other than the Product Deposit Account; provided, that prior to delivery of a Notice of Exclusive Control, Grantor will sweep deposits from the Product Deposit Account to
other deposit accounts in its name on a regular basis. 
  
 (i) With respect to the Marketed Product NDAs (i) nothing has come to the attention of the Grantor which has led the Grantor to reasonably believe that any of the Marketed Product NDAs are not in good standing with the FDA and (ii) to the
best of Grantor’s knowledge, there is no action or proceeding by any governmental or regulatory authority pending or threatened seeking the revocation or suspension of any regulatory approval relating to the sale of any Marketed Product in the
Territory. 
  
 (j) As to itself and its Product
Intellectual Property Collateral: 
  
 (i) To the
best of Grantor’s knowledge, the Grantor’s use of the Product Intellectual Property Collateral does not conflict with, infringe, misappropriate, dilute, misuse or otherwise violate the intellectual property rights of any third party.

  
 (ii) The Grantor is the exclusive owner of
all right, title and interest in and to the Product Intellectual Property Collateral (other than the Product Intellectual Property Collateral which has been licensed to the Grantor), and is 

  

 -10- 

 
entitled to use all Product Intellectual Property Collateral subject only to the terms of the Product IP Agreements. 
  
 (iii) The Product Intellectual Property Collateral set forth
in Schedule V hereto includes all of the patents, patent applications, domain names, trade dress, trademark registrations and applications, copyright registrations and applications and Product IP Agreements owned by or licensed to the Grantor which
primarily relate to the manufacture, packaging, marketing, distribution, promotion, co-marketing, co-promotion, sale, offer for sale and importation of the Product in the Territory. 
  
 (iv) The Product Intellectual Property Collateral has not been adjudged invalid or unenforceable in whole or
part, and to the best of the Grantor’s knowledge, is valid and enforceable. The Grantor is not aware of any uses of any item of Product Intellectual Property Collateral that could be expected to lead to such item becoming invalid or
unenforceable. 
  
 (v) The Grantor will, within
10 days after the date of this Agreement, make all required filings and recordings and pay all required fees and taxes to record its interests in the Purchased Patents and Purchased Trademarks with the U.S. Patent and Trademark Office and record its
interests in the registered Purchased Copyrights, if any, with the U.S. Copyright Office. 
  
 (vi) No claim, action, suit, investigation, litigation or proceeding has been asserted or is pending or, to the best of Grantor’s
knowledge, threatened against the Grantor (i) based upon or challenging or seeking to deny or restrict the Grantor’s rights in or use of any of the Product Intellectual Property Collateral, (ii) alleging that the Grantor’s rights in or use
of the Product Intellectual Property Collateral with respect to the manufacture, production, shipment, marketing, sale or distribution of the Product in the Territory infringe, misappropriate, dilute, misuse or otherwise violate any patent,
trademark, copyright or any other proprietary right of any third party, or (iii) alleging that the Product Intellectual Property Collateral is being licensed or sublicensed in violation or contravention of the terms of any license or other
agreement. Except as set forth in Schedule V hereto, to the best of Grantor’s knowledge, no Person is engaging in any activity that infringes, misappropriates, dilutes, misuses or otherwise violates the Product Intellectual Property Collateral
or the Grantor’s rights in or use thereof in a manner that would have a material adverse effect on the Grantor. Except as set forth in Schedule V hereto, the Grantor has not granted any license, release, covenant not to sue, non-assertion
assurance, or other right to any Person with respect to any part of the Product Intellectual Property Collateral. The consummation of the transactions contemplated by the Indentures or the Transfer Agreement will not result in the termination or
impairment of any of the Product Intellectual Property Collateral. 
  
 (vii) With respect to each IP Agreement: (A) to the best of Grantor’s knowledge, such IP Agreement is valid and binding and in full force and effect 

  

 -11- 

 
and represents the entire agreement between the respective parties thereto with respect to the subject matter thereof; (B) to the best of Grantor’s
knowledge, (I) such IP Agreement will not cease to be valid and binding and in full force and effect on terms identical to those currently in effect as a result of the rights and interest granted herein, and (II) the grant of such rights and
interest will not constitute a material breach or default under such IP Agreement or otherwise give any party thereto a right to terminate such IP Agreement; (C) the Grantor has not received any written notice of termination or cancellation under
such IP Agreement; (D) the Grantor has not received any written notice of a material breach or default under such IP Agreement, which breach or default has not been cured; (E) the Grantor has not granted to any other third party any rights, adverse
or otherwise, under such IP Agreement other than as set forth in this Agreement; and (F) to the best of Grantor’s knowledge, (I) neither the Grantor nor any other party to such IP Agreement is in breach or default thereof in any material
respect, and (II) no event has occurred that, with notice or lapse of time or both, would constitute such a material breach or default or permit termination, modification or acceleration under such IP Agreement. 
  
 (viii) To the best of the Grantor’s knowledge, (A) none
of the Product Trade Secrets of the Grantor has been divulged, disclosed or misappropriated from the Grantor or to the material detriment of the Grantor for the benefit of any other Person other than the Grantor; (B) no employee, independent
contractor or agent of the Grantor has misappropriated any trade secrets of any other Person in the course of the performance of his or her duties as an employee, independent contractor or agent of the Grantor with respect to the Product
Intellectual Property Collateral; and (C) no employee, independent contractor or agent of the Grantor is in material default or breach of any term of any employment agreement, non-disclosure agreement, assignment of inventions agreement or similar
agreement or contract relating in any way to the protection, ownership, development, use or transfer of the Grantor’s Product Intellectual Property Collateral. 
  
 (ix) Except for the Prior Rights Agreements (as defined in Schedule II hereto), neither the Grantor nor the
Product Intellectual Property Collateral is subject to any outstanding consent, settlement, decree, order, injunction, judgment or ruling restricting the Grantor’s use of the Product Intellectual Property Collateral with respect to the
manufacture, production, shipment, marketing, sale or distribution of the Product in the Territory that would impair the validity or enforceability of such Product Intellectual Property Collateral in a manner that would have a material adverse
effect on the Grantor. 
  
 Section 6. Further Assurances.

  
 (a) The Grantor agrees that from time to
time, at the expense of the Grantor, the Grantor will promptly execute and deliver, or otherwise authenticate, all further instruments and documents, and take all further action that may be necessary or desirable, or that the Collateral Agent may
request, in order to perfect and protect any pledge or security interest granted or purported to be granted by the Grantor hereunder or to enable the Collateral Agent to 

  

 -12- 

 
exercise and enforce its rights and remedies hereunder with respect to any Collateral of the Grantor. Without limiting the generality of the foregoing, the
Grantor will promptly with respect to Collateral of the Grantor: (i) at the request of the Collateral Agent, mark conspicuously each document included in Inventory, Product Receivables or Product Receivables Agreements, and each Product IP
Agreement, Product Agreement and Assigned Agreement and, each of its records pertaining to such Collateral with a legend, in form and substance reasonably satisfactory to the Collateral Agent, indicating that such document, Product Receivable,
Product Receivable Agreement, Product IP Agreement, Product Agreement, Assigned Agreement or other Collateral is subject to the security interest granted hereby; (ii) execute or authenticate and file such financing or continuation statements, or
amendments thereto, and such other instruments or notices, as may be necessary or desirable, or as the Collateral Agent may reasonably request, in order to perfect and preserve the security interest granted or purported to be granted by the Grantor
hereunder; and (iii) deliver to the Collateral Agent evidence that all other action that the Collateral Agent may deem reasonably necessary or desirable in order to perfect and protect the security interest created by the Grantor under this
Agreement has been taken. Upon request by the Collateral Agent, the Grantor will, at the Grantor’s expense, cause to be delivered to the Collateral Agent, for the benefit of the Secured Parties, an opinion of counsel, from outside counsel
reasonably satisfactory to the Collateral Agent, as to such matters relating to the transactions contemplated hereby as the Collateral Agent may reasonably request; provided that the Collateral Agent shall be limited to one such request per
calendar year. 
  
 (b) The Grantor hereby
authorizes the Collateral Agent to file one or more financing or continuation statements, and amendments thereto, in each case without the signature of the Grantor, with respect to the Collateral. A photocopy or other reproduction of this Agreement
or any financing statement covering the Collateral or any part thereof shall be sufficient as a financing statement where permitted by law. The Grantor ratifies its authorization for the Collateral Agent to have filed such financing statements,
continuation statements or amendments filed prior to the date hereof. 
  
 (c) The Grantor will furnish to the Collateral Agent from time to time statements and schedules further identifying and describing the Collateral of the Grantor and such other reports in connection with such
Collateral as the Collateral Agent may reasonably request, all in reasonable detail. 
  
 (d) Upon request of the Collateral Agent, the Grantor will, at the Grantor’s expense, cause to be delivered to the Collateral Agent,
for the benefit of the Secured Parties, undated letters executed by the Grantor with respect to each new drug application set forth in Schedule VII providing the FDA notice of the transfer of all such drug applications (each, an “NDA
Transfer Letter”), in substantially the form of Exhibit C hereto. 
  
 (e) The Grantor shall, as soon a practically possible after receipt of such documents from Lilly, provide to the Collateral Agent true and
complete copies of each of the new drug applications and investigational new drug applications as filed with the FDA and as set forth in Schedule VII hereto, together with all supplements, pending supplements, amendments and reports with respect
thereto contemplated by 21 C.F.R. § 314.81 as of the date of delivery. 
  

 -13- 

 Section 7. As to Product Equipment and Product Inventory. 
  
 (a) The Grantor will keep the Product Equipment and Product
Inventory (other than Product Inventory sold in the ordinary course of business) at the places therefor specified in Section 5(b) or, upon written notice to the Collateral Agent within thirty (30) days after establishing any new location for Product
Equipment or Product Inventory, at such other places designated by the Grantor in such notice. Upon the giving of such notice, Schedule III shall be automatically amended to add any new locations specified in the notice. 
  
 (b) The Grantor will cause the Product Equipment of the
Grantor to be maintained and preserved in the same condition, repair and working order as when acquired, ordinary wear and tear excepted, and will make or cause to be made all repairs, replacements and other improvements in connection with the
Product Equipment that are necessary or desirable to such end; provided, that the Grantor shall not be required to maintain and preserve or repair, replace or make any improvements to any of the Product Equipment if the Grantor shall determine that
the maintenance, preservation, replacement or improvement of such Product Equipment is not desirable in the conduct of the Grantor’s business and that the failure to do so will not be materially disadvantageous to its business or to the Secured
Parties. 
  
 (c) The Grantor will pay promptly
when due all property and other taxes, assessments and governmental charges or levies imposed upon, and all claims (including, without limitation, claims for labor, materials and supplies) against, the Product Equipment and Product Inventory of the
Grantor; provided, that the Grantor shall not be required to pay any such tax, assessment, governmental charge or levy, or claim (i) if the failure to do so would not be materially disadvantageous to the Grantor’s business or to the
Secured Parties or (ii) if the amount, applicability or validity thereof is being contested in good faith by appropriate proceedings. In producing its Product Inventory, the Grantor will comply in all material respects with all requirements of
applicable law, including, without limitation, the Fair Labor Standards Act. 
  
 Section 8. Insurance. 
  
 (a) The Grantor will, at its own expense, maintain insurance with respect to the Product Equipment and Product Inventory of the Grantor in such amounts, against such risks, in such form and with such insurers, as
shall be reasonably satisfactory to the Collateral Agent from time to time. Each such policy shall in addition (i) name the Grantor and the Collateral Agent as insured parties and loss payees thereunder (without any representation or warranty by or
obligation upon the Collateral Agent) as their interests may appear, (ii) provide that there shall be no recourse against the Collateral Agent for payment of premiums or other amounts with respect thereto and (iii) provide that at least 10
days’ prior written notice of cancellation or of lapse shall be given to the Collateral Agent by the insurer. The Grantor will, if so requested by the Collateral Agent, deliver to the Collateral Agent original or duplicate policies of such
insurance. 
  
 (b) In case of any loss involving
damage to Product Equipment or Product Inventory when subsection (c) of this Section 8 is not applicable, (i) the Grantor will make or cause to be made the necessary repairs to or replacements of such Product Equipment or Product Inventory and (ii)
any proceeds of insurance properly received by or released to the Grantor shall be used by the Grantor, except as otherwise required hereunder, to pay or as reimbursement for 

  

 -14- 

 
the costs of such repairs or replacements; provided that, in each case, the Grantor shall not be required to make such repairs or replacements if the
Grantor shall determine that paying for the costs of such repairs or replacements is not desirable in the conduct of the Grantor’s business and that the failure to do so will not be materially disadvantageous to its business, to the value of
the Collateral (taken as a whole) or to the Secured Parties. 
  
 (c) If an Event of Default shall have occurred and be continuing, all insurance payments received by the Collateral Agent in connection with any loss, damage or destruction of any Product Inventory or Product
Equipment will be released by the Collateral Agent to the Grantor for the repair, replacement or restoration thereof, subject to such terms and conditions with respect to the release thereof as the Collateral Agent may reasonably require. To the
extent that the amount of any such insurance payments exceeds the cost of any such repair, replacement or restoration, the Collateral Agent will not be required to release the amount thereof to the Grantor and may hold or continue to hold such
amount as additional security for the Secured Obligations of the Grantor. 
  
 Section 9. Post-Closing Changes; Bailees; Collections on Product IP Agreements, Product Agreements, and Assigned Agreements; NDAs. 
  
 (a) The Grantor will not change its name, type of organization, jurisdiction of organization, organizational
identification number or location from those referenced in Section 5(a) of this Agreement without first giving at least 30 days’ prior written notice to the Collateral Agent and taking all action reasonably required by the Collateral Agent for
the purpose of perfecting or protecting the security interest granted by this Agreement. The Grantor will not change the location of the Product Equipment and Product Inventory from the locations therefor specified in Sections 5(a) and 5(b) without
giving the Collateral Agent written notice within thirty days after such change. The Grantor will hold and preserve its records relating to the Collateral, including, without limitation, the Product IP Agreements, Product Agreements and Assigned
Agreements, and will permit representatives of the Collateral Agent at any time during normal business hours and upon at least five (5) calendar days’ prior written notice to inspect and make abstracts from such records and other documents;
provided, that, so long as no Event of Default has occurred and is continuing, the Collateral Agent shall be limited to one such inspection per calendar year. If the Grantor does not have an organizational identification number and later obtains
one, it will forthwith notify the Collateral Agent of such organizational identification number. 
  
 (b) If any Collateral of the Grantor is at any time in the possession or control of a warehouseman, bailee or agent and if the Collateral
Agent so requests the Grantor will (i) notify such warehouseman, bailee or agent of the security interest created hereunder, (ii) instruct such warehouseman, bailee or agent to hold all such Collateral solely for the Collateral Agent’s account
subject only to the Collateral Agent’s instructions (which shall permit such Collateral to be removed by the Grantor in the ordinary course of business until the Collateral Agent notifies such warehouseman, bailee or agent that an Event of
Default has occurred and is continuing), (iii) use commercially reasonable efforts to cause such warehouseman, bailee or agent to authenticate a record acknowledging that it holds possession of such Collateral for the Collateral Agent’s benefit
and shall act solely on the instructions of the Collateral Agent without the further consent of the Grantor or any other Person from and after the time that such warehouseman, 

  

 -15- 

 
bailee or agent receives written notice from the Collateral Agent that an Event of Default has occurred and is continuing, and (iv) make such authenticated
record available to the Collateral Agent. 
  
 (c)
Except as otherwise provided in this subsection (c), the Grantor will continue to collect, at its own expense, all amounts due or to become due the Grantor under the Product IP Agreements, Product Agreements and Assigned Agreements. In connection
with such collections, the Grantor may take (and, at the Collateral Agent’s direction upon the occurrence and during the continuance of an Event of Default, will take) such action as the Grantor (or, upon the occurrence and during the
continuance of an Event of Default, the Collateral Agent) may deem necessary or advisable to enforce collection of the Product IP Agreements, Product Agreements and Assigned Agreements; provided, however, that the Collateral Agent
shall have the right at any time, upon the occurrence and during the continuance of an Event of Default and upon written notice to the Grantor of its intention to do so, to notify the obligors under any Product IP Agreements, Product Agreements, or
Assigned Agreements of the assignment of such Product IP Agreements, Product Agreements or Assigned Agreements to the Collateral Agent and to direct such obligors to make payment of all amounts due or to become due to the Grantor thereunder directly
to the Collateral Agent and, upon such notification and at the expense of the Grantor, to enforce collection of any such Product IP Agreements, Product Agreements or Assigned Agreements, to adjust, settle or compromise the amount or payment thereof,
in the same manner and to the same extent as the Grantor might have done, and to otherwise exercise all rights with respect to such Product IP Agreements, Product Agreements or Assigned Agreements, including, without limitation, those set forth set
forth in Section 9-607 of the UCC. After receipt by the Grantor of the notice from the Collateral Agent referred to in the proviso to the preceding sentence and during the continuance of the applicable Event of Default, (i) all amounts and proceeds
(including, without limitation, instruments) received by the Grantor in respect of the Product IP Agreements, Product Agreements and Assigned Agreements shall be received in trust for the benefit of the Collateral Agent hereunder, shall be
segregated from other funds of the Grantor and shall be forthwith paid over to the Collateral Agent in the same form as so received (with any necessary endorsement) to be either (A) released to the Grantor to be applied to the Secured Obligations of
the Grantor so long as no Event of Default shall have occurred and be continuing or (B) if any Event of Default shall have occurred and be continuing, applied as provided in Section 17(b) and (ii) the Grantor will not adjust, settle or compromise
the amount or payment of any amount due on any Product IP Agreements, Product Agreements or Assigned Agreements, release wholly or partly any obligor thereof, or allow any credit or discount thereon. If an Event of Default has occurred and is then
continuing, the Grantor will not permit or consent to the subordination of its right to payment under any of the Product Agreements to any other indebtedness or obligations of the obligor thereunder, without the consent of the Collateral Agent.

  
 (d) The Grantor covenants and agrees to
maintain the Marketed Product NDAs in full force and effect, unless the Grantor shall have determined that the maintenance or enforcement of any Marketed Product NDA is no longer desirable in the conduct of the Grantor’s business and that the
failure to do so will not be materially disadvantageous to its business or to the Secured Parties. This obligation of the Grantors shall not extend to Discontinued Product ANDAs. 
  

 -16- 

 Section 10. As to Intellectual Property Collateral. 
  
 (a) With respect to each material item of its Product
Intellectual Property Collateral, the Grantor agrees to take, at its expense, all commercially reasonable steps, including, without limitation and to the extent applicable, in the U.S. Patent and Trademark Office, the U.S. Copyright Office and any
other governmental authority, to (i) maintain the confidentiality of the Product Trade Secrets and the validity and enforceability of all Product Patents, Product Trademarks and registered Product Copyrights, if any, in accordance with the terms of
Section 10(d) hereof, and (ii) pursue the registration and maintenance of each patent, trademark, or copyright registration or application, now or hereafter included in such Product Intellectual Property Collateral owned by the Grantor, including,
without limitation, the payment of required fees and taxes, the filing of responses to office actions issued by the U.S. Patent and Trademark Office, the U.S. Copyright Office or other governmental authorities, the filing of applications for renewal
or extension, the filing of affidavits under Sections 8 and 15 of the U.S. Trademark Act, the filing of divisional, continuation, continuation-in-part, reissue and renewal applications or extensions, the payment of maintenance fees and the
participation in interference, reexamination, opposition, cancellation, infringement and misappropriation proceedings; provided, that, unless an Event of Default shall have occurred and then be continuing, the Grantor shall not be required to make
any of the filings, pay any of the amounts or take any of the actions described in this Section 10(a) (other than the registration and maintenance of the Purchased Trademarks in the U.S. Patent and Trademark Office and the payment of related fees
and taxes) if the Grantor shall determine that the making of such filings, the paying of any such amounts or the taking of such actions is not desirable in the conduct of the Grantor’s business and that the failure to do so will not be
materially disadvantageous to its business, to the value of the Collateral (taken as a whole) or to the Secured Parties. If an Event of Default has occurred and is continuing, the Grantor shall not, without the written consent of the Collateral
Agent, discontinue use of or otherwise abandon any material Product Intellectual Property Collateral, or abandon any right to file an application for patent, trademark or copyright. 
  
 (b) The Grantor agrees promptly to notify the Collateral Agent if the Grantor becomes aware (i) that any
material item of the Product Patents, Product Trademarks or registered Product Copyrights, if any, have been held by a final, binding and non-appealable order of any court invalid or unenforceable in the Territory, or (ii) of any final, binding and
non-appealable adverse determination by any governmental authority regarding the Grantor’s ownership of any material item of the Product Intellectual Property Collateral or its right to register the same in the Territory. 
  
 (c) In the event that the Grantor becomes aware that any
material item of the Product Intellectual Property Collateral is being infringed or misappropriated by a third party, the Grantor shall promptly notify the Collateral Agent and, to the extent permitted by applicable law, take such commercially
reasonable actions, at its expense, as the Grantor deems reasonable and appropriate under the circumstances to protect or enforce such Product Intellectual Property Collateral, including, without limitation, suing for infringement or
misappropriation and for an injunction against such infringement or misappropriation, subject to the provisions of the Transfer Agreement or the applicable Product IP Agreement; provided, that, unless an Event of Default shall have occurred and then
be continuing, the Grantor shall not be required to provide such notice or take any such actions if the Grantor shall determine that the taking of such actions 

  

 -17- 

 
is not desirable in the conduct of the Grantor’s business and that the failure to do so will not be materially disadvantageous to its business or to the
Secured Parties. 
  
 (d) The Grantor shall, to
the extent required by law, use proper statutory notice in connection with its use of each material item of its Product Intellectual Property Collateral. The Grantor shall not do or permit any act or knowingly omit to do any act whereby any of its
Product Patents, Product Trademarks or registered Product Copyrights, if any, may lapse or become invalid or unenforceable or any of its Product Trade Secrets may be placed in the public domain unless the Grantor has determined that such Product
Patents, Product Trademarks, registered Product Copyrights (if any) and Product Trade Secrets are no longer desirable in the conduct of the Grantor’s business and that the failure to do so will not be materially disadvantageous to its business
or to the Secured Parties; provided, that such determination may not be made by the Grantor without the written consent of the Collateral Agent if an Event of Default has occurred and is then continuing. 
  
 (e) With respect to its Product Patents, registered Product
Trademarks and registered Product Copyrights, if any, the Grantor agrees to execute or otherwise authenticate an agreement, in substantially the form set forth in Exhibit A hereto or otherwise in form and substance satisfactory to the Collateral
Agent (an “Intellectual Property Security Agreement”), for recording the security interest granted hereunder to the Collateral Agent in such Product Patents, registered Product Trademarks and registered Product Copyrights, if
any, with the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other governmental authorities necessary to perfect the security interest hereunder in such Product Patent, registered Product Trademarks and registered Product
Copyrights, if any. 
  
 (f) The Grantor agrees
that should it obtain an ownership interest in any item of the type set forth in Section 1(i) that is not on the date hereof a part of the Product Intellectual Property Collateral (“After-Acquired Intellectual Property”) (i)
the provisions of this Agreement shall automatically apply thereto, and (ii) any such After-Acquired Intellectual Property and, in the case of trademarks, the goodwill symbolized thereby, shall automatically become part of the Product Intellectual
Property Collateral subject to the terms and conditions of this Agreement with respect thereto. The Grantor shall give prompt written notice to the Collateral Agent identifying Product Patents, registered Product Trademarks and registered Product
Copyrights comprising a part of the After-Acquired Intellectual Property, and the Grantor shall execute and deliver to the Collateral Agent with such written notice, or otherwise authenticate, an IP Security Agreement Supplement substantially in the
form of Exhibit B hereto or otherwise in form and substance reasonably satisfactory to the Collateral Agent covering such Product Patents, registered Product Trademarks and registered Product Copyrights which IP Security Agreement Supplement shall
be recorded with the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other governmental authorities necessary to perfect the security interest hereunder in such Product Patents, registered Product Trademarks and registered
Product Copyrights. 
  

 -18- 

 Section 11. As to the Product IP Agreements, Product Agreements and Assigned Agreements.

  
 (a) The Grantor will at its expense:

  
 (i) (x) perform and observe all terms and
provisions of the Product IP Agreements, Product Agreements and Assigned Agreements to be performed or observed by it, except where the failure to so perform and observe such terms and provisions would not have a material adverse effect on the
Grantor or on the value of the Collateral (taken as a whole); (y) maintain the Product IP Agreements, Product Agreements and Assigned Agreements to which it is a party in full force and effect and enforce the Product IP Agreements, Product
Agreements and Assigned Agreements to which it is a party in accordance with the terms thereof unless the Grantor shall have determined that the maintenance or enforcement of such Product IP Agreements, Product Agreements or Assigned Agreements is
no longer desirable in the conduct of the Grantor’s business and that the failure to do so will not be materially disadvantageous to its business, to the value of the Collateral (taken as a whole) or to the Secured Parties; and (z) upon the
occurrence and during the continuance of an Event of Default, take all such action to such end as may be reasonably requested from time to time by the Collateral Agent with respect to such Product IP Agreements, Product Agreements or Assigned
Agreements; and 
  
 (ii) upon the occurrence and
during the continuance of an Event of Default (A) furnish to the Collateral Agent promptly upon receipt thereof copies of all material notices, requests and other documents received by the Grantor under or pursuant to the Product IP Agreements,
Product Agreements or Assigned Agreements to which it is a party, (B) furnish to the Collateral Agent such information and reports regarding the Product IP Agreements, Product Agreements or Assigned Agreements and such other Collateral of the
Grantor as the Collateral Agent may reasonably request and (C) upon request of the Collateral Agent make to each other party to any Product IP Agreements, Product Agreement or Assigned Agreement to which it is a party such demands and requests for
information and reports or for action as the Grantor is entitled to make thereunder. 
  
 (b) The Grantor agrees that it will not: 
  
 (i) cancel or terminate before its scheduled expiration date any Product IP Agreement, Product Agreement or Assigned Agreement to which it
is a party or consent to or accept any cancellation or termination thereof; 
  
 (ii) amend, amend and restate, supplement or otherwise modify any such Product IP Agreement, Product Agreement or Assigned Agreement or give any consent, waiver or approval thereunder; or 
  
 (iii) waive any default under or breach of any such Product
IP Agreement, Product Agreement or Assigned Agreement; 
  
 unless, in any of the
foregoing cases, the Grantor shall have determined that the taking of any such actions is desirable in the conduct of the Grantor’s business and will not be materially disadvantageous to its business, to the value of the Collateral (taken as a
whole) or to the Secured 

  

 -19- 

 
Parties; provided, that such determination may not be made by the Grantor without the written consent of the Collateral Agent if an Event of Default has
occurred and is then continuing. 
  
 (c) At the
request of the Collateral Agent made at any time following the occurrence and during the continuance of an Event of Default, the Grantor will make commercially reasonable efforts to cause each party to the Product IP Agreements, Product Agreements
and Assigned Agreements to which the Grantor is a party to execute and deliver to such Grantor a consent and agreement, in form and substance reasonably satisfactory to the Collateral Agent, to the assignment of the Product IP Agreement Collateral,
Product Agreement Collateral or Assigned Agreement Collateral to the Collateral Agent pursuant to this Agreement. 
  
 Section 12. Payments Under the Product IP Agreements, Product Agreements and Assigned Agreements. 
  
 (a) Upon the occurrence and during the continuance of an
Event of Default, the Grantor shall, upon the Collateral Agent’s written request, instruct each other party to each Product IP Agreement, Product Agreement and Assigned Agreement to which it is a party that all payments due or to become due
under or in connection with such Product IP Agreement, Product Agreement or Assigned Agreement will be made directly to the Collateral Agent. 
  
 (b) All moneys received or collected pursuant to subsection (a) above shall be applied as provided in Section 17(b). 
  
 Section 13. Transfers and Other Liens. The Grantor agrees that
it will not (a) sell, assign or otherwise dispose of, or grant any option with respect to, any of the Collateral (other than Product Inventory in the ordinary course of business and Product Equipment if the Grantor shall have determined that such
Product Equipment is no longer desirable in the conduct of the Grantor’s business and the sale, assignment and disposition of such Product Equipment will not be materially disadvantageous to its business, to the value of the Collateral (taken
as a whole) or to the Secured Parties), without the prior written consent of the Collateral Agent, or (ii) create or suffer to exist any Lien upon or with respect to any of the Collateral of the Grantor except for the pledge, assignment and security
interest created under this Agreement and Permitted Encumbrances; provided, that nothing contained in this Section 13 shall prohibit the Grantor from granting in the ordinary course of business pursuant to a transaction not tantamount to a sale any
license or sublicense to any of the Product Intellectual Property Collateral. 
  
 Section 14. Collateral Agent Appointed Attorney-in-Fact. The Grantor hereby irrevocably appoints the Collateral Agent the Grantor’s attorney-in-fact, with full authority in the place and stead of the
Grantor and in the name of the Grantor or otherwise, from time to time after the occurrence and during the continuance of an Event of Default and in the Collateral Agent’s discretion, to take any action and to execute any instrument that the
Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement, including, without limitation: 
  
 (a) to obtain and adjust insurance required to be paid to the Collateral Agent pursuant to Section 8, 
  

 -20- 

 (b) to ask for, demand, collect, sue for, recover, compromise, receive and give
acquittance and receipts for moneys due and to become due under or in respect of any of the Collateral, 
  
 (c) to receive, indorse and collect any drafts or other instruments, documents and chattel paper, in connection with clause (a) or (b)
above, and 
  
 (d) to file any claims or take any
action or institute any proceedings that the Collateral Agent may deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce compliance with the terms and conditions of any Product IP Agreement, Product Agreement
or Assigned Agreement or the rights of the Collateral Agent with respect to any of the Collateral. 
  
 Section 15. Collateral Agent May Perform. If the Grantor fails to perform any agreement contained herein within 5 days after the Grantor’s
receipt of written notice from the Collateral Agent of such failure, the Collateral Agent may, as the Collateral Agent deems necessary to protect the security interest granted hereunder in the Collateral or to protect the value thereof, but without
any obligation to do so and without notice, itself perform, or cause performance of, such agreement, and the expenses of the Collateral Agent incurred in connection therewith shall be payable by the Grantor under Section 18. 
  
 Section 16. The Collateral Agent’s Duties. 
  
 (a) The powers conferred on the Collateral Agent hereunder
are solely to protect the Secured Parties’ interest in the Collateral and shall not impose any duty upon it to exercise any such powers. Except for the safe custody of any Collateral in its possession, if any, and the accounting for moneys
actually received by it hereunder, and as otherwise provided in Section 16(c), the Collateral Agent shall have no duty as to any Collateral, as to ascertaining or taking action with respect to calls, conversions, exchanges, maturities, tenders or
other matters relative to any Collateral, whether or not any Secured Party has or is deemed to have knowledge of such matters, or as to the taking of any necessary steps to preserve rights against any parties or any other rights pertaining to any
Collateral. The Collateral Agent shall be deemed to have exercised reasonable care in the custody and preservation of any Collateral in its possession if such Collateral is accorded treatment substantially equal to that which it accords its own
property. 
  
 (b) Anything contained herein to
the contrary notwithstanding, the Collateral Agent may from time to time and upon prior written notice to the Grantor, when the Collateral Agent deems it to be necessary, appoint one or more subagents (each a “Subagent”) for
the Collateral Agent hereunder with respect to all or any part of the Collateral. In the event that the Collateral Agent so appoints any Subagent with respect to any Collateral, (i) the assignment and pledge of such Collateral and the security
interest granted in such Collateral by the Grantor hereunder shall be deemed for purposes of this Security Agreement to have been made to such Subagent, in addition to the Collateral Agent, for the ratable benefit of the Secured Parties, as security
for the Secured Obligations of the Grantor, (ii) such Subagent shall automatically be vested, in addition to the Collateral Agent, with all rights, powers, privileges, interests and remedies of the Collateral Agent hereunder with respect to such
Collateral, (iii) the Subagent 

  

 -21- 

 
shall execute and deliver to the Grantor an agreement in form and substance reasonably satisfactory to the Grantor and the Collateral Agent pursuant to which
the Subagent agrees to be bound by all of the provisions of this Agreement which are applicable to the Collateral Agent and (iv) the term “Collateral Agent,” when used herein in relation to any rights, powers, privileges, interests and
remedies of the Collateral Agent with respect to such Collateral, shall include such Subagent; provided, however, that (x) no such Subagent shall be authorized to take any action with respect to any such Collateral unless and except to
the extent expressly authorized in writing by the Collateral Agent and (y) in no event shall any Subagent be a direct or indirect supplier, customer or competitor of the Grantor. 
  
 (c) The Collateral Agent agrees that it will keep confidential and will not disclose, divulge or use for any
purpose any information which the Collateral Agent may obtain, directly or indirectly, from the Grantor or any of the Grantor’s agents including, without limitation, any and all Product Trade Secrets and any and all information contained in
reports and other materials and information submitted or made available by the Grantor to the Collateral Agent (the “Confidential Information”), unless such Confidential Information is generally known, or until such
Confidential Information becomes generally known, to the public (other than as a result of a breach of this Section 16(c)); provided, however, that the Collateral Agent may disclose Confidential Information (a) to its attorneys,
accountants, consultants, and other professionals to the extent necessary to obtain their respective services in connection with the Collateral Agent’s rights and obligations as collateral agent under this Agreement, (b) as may otherwise be
required by law; provided, that the Collateral Agent provides the Grantor prompt written notice thereof before making any such disclosure and provides reasonable cooperation to the Grantor at the Grantor’s expense to obtain a protective order
or other similar determination with respect to the Confidential Information that may be required to be disclosed, or (c) to the extent necessary to exercise its right to foreclosure and sale proceedings as contemplated in Section 17 in respect of
the Collateral upon the occurrence and during the continuance of an Event of Default. 
  
 (d) The Collateral Agent covenants and agree that unless an Event of Default has occurred and is continuing, it shall not: (i) deliver any
NDA Transfer Letter to the FDA or assert rights to ownership of the new drug applications or applications covered thereby or (ii) deliver a Notice of Exclusive Control (as defined in the Deposit Account Control Agreement) or any similar document to
the Pledged Account Bank or assert rights of dominion or control over the Product Deposit Account. 
  
 Section 17. Remedies. If any Event of Default shall have occurred and be continuing: 
  
 (a) The Collateral Agent may exercise in respect of the Collateral, in addition to other rights and remedies
provided for herein or otherwise available to it, all the rights and remedies of a secured party upon default under the UCC (whether or not the UCC applies to the affected Collateral) and also may: (i) require the Grantor to, and the Grantor hereby
agrees that it will at its expense and upon request of the Collateral Agent forthwith, assemble all or part of the Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place and time to be designated by
the Collateral Agent that is reasonably convenient to both parties; (ii) without notice except as specified below, sell the Collateral or any part thereof in one or more parcels at public or private sale, at any of the Collateral Agent’s
offices or elsewhere, for 

  

 -22- 

 
cash, on credit or for future delivery, and upon such other terms as the Collateral Agent may deem commercially reasonable; (iii) occupy any premises owned
or leased by the Grantor where the Collateral or any part thereof is assembled or located for a reasonable period in order to effectuate its rights and remedies hereunder or under law, without obligation to the Grantor in respect of such occupation;
and (iv) exercise any and all rights and remedies of the Grantor under or in connection with the Collateral, or otherwise in respect of the Collateral, including, without limitation, (A) any and all rights of the Grantor to demand or otherwise
require payment of any amount under, or performance of any provision of, the Product IP Agreements, the Product Agreements, the Assigned Agreements, the Product Receivables, the Product Receivables Agreements and the other Collateral, (B) withdraw,
or cause or direct the withdrawal, of all funds with respect to the Account Collateral and (C) exercise all other rights and remedies with respect to the Product IP Agreements, the Product Agreements, the Assigned Agreements, the Product
Receivables, the Product Receivables Agreements the and the other Collateral, including, without limitation, those set forth in Section 9-607 of the UCC. The Grantor agrees that, to the extent notice of sale shall be required by law, at least ten
days’ notice to the Grantor of the time and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. The Collateral Agent shall not be obligated to make any sale of Collateral
regardless of notice of sale having been given. The Collateral Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and
place to which it was so adjourned. 
  
 (b) Any
cash held by or on behalf of the Collateral Agent and all cash proceeds received by or on behalf of the Collateral Agent in respect of any sale of, collection from, or other realization upon all or any part of the Collateral may, in the discretion
of the Collateral Agent, be held by the Collateral Agent as collateral for, and/or then or at any time thereafter applied (after payment of any amounts payable to the Collateral Agent pursuant to Section 16) in whole or in part by the Collateral
Agent for the ratable benefit of the Secured Parties against, all or any part of the Secured Obligations, in accordance with the terms of the Indentures. Any surplus of such cash or cash proceeds held by or on the behalf of the Collateral Agent and
remaining after payment in full of all the Secured Obligations shall be paid over to the Grantor or to whomsoever may be lawfully entitled to receive such surplus. 
  
 (c) All payments received by the Grantor under or in connection with any Product IP Agreement, Product
Agreement or Assigned Agreement or otherwise in respect of the Collateral shall be received in trust for the benefit of the Collateral Agent, shall be segregated from other funds of the Grantor and shall be forthwith paid over to the Collateral
Agent in the same form as so received (with any necessary indorsement). 
  
 (d) In the event of any sale or other disposition of any of the Product Intellectual Property Collateral of the Grantor at the action of the Collateral Agent, the goodwill symbolized by any Product Trademarks subject
to such sale or other disposition shall be included therein, and the Grantor shall supply to the Collateral Agent or its designee the Grantor’s know-how and expertise, and documents and things relating to any Product Intellectual Property
Collateral subject to such sale or other disposition, and the Grantor’s customer lists and other records and documents relating to such Product Intellectual Property Collateral and to the manufacture, distribution, advertising and sale of
products and services of the Grantor. 
  

 -23- 

 (e) The Collateral Agent may (i) complete each NDA Transfer Letter indicating the name of
the transferee and dating the NDA Transfer Letter, (ii) forward the NDA Transfer Letter to the FDA and (iii) assert all rights to ownership of the new drug application or applications covered thereby. 
  
 Section 18. Indemnity and Expenses. 
  
 (a) The Grantor agrees to indemnify, defend and save and
hold harmless each Secured Party and each of their Affiliates and their respective officers, directors, employees, agents and advisors (each, an “Indemnified Party”) from and against, and shall pay on demand, any and all
claims, damages, losses, liabilities and expenses (including, without limitation, reasonable fees and expenses of counsel) that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection
with or resulting from this Agreement (including, without limitation, enforcement of this Agreement), except to the extent such claim, damage, loss, liability or expense is found in a final, non-appealable judgment by a court of competent
jurisdiction to have resulted from such Indemnified Party’s gross negligence or willful misconduct. 
  
 (b) The Grantor will upon demand pay to the Collateral Agent the amount of any and all reasonable expenses, including, without limitation,
the reasonable fees and expenses of its counsel and of any experts and agents, that the Collateral Agent may incur in connection with (i) the administration of this Agreement, (ii) the custody, preservation, use or operation of, or the sale of,
collection from or other realization upon, any of the Collateral of the Grantor, (iii) the exercise or enforcement of any of the rights of the Collateral Agent or the other Secured Parties hereunder or (iv) the failure by the Grantor to perform or
observe any of the provisions hereof. 
  
 Section 19.
Amendments; Waivers. No amendment or waiver of any provision of this Agreement, and no consent to any departure by any party hereto from any provision of this Agreement shall in any event be effective unless the same shall be in writing and
signed by the Collateral Agent, the Grantor, and the Holders of not less than a majority in aggregate principal amount of the Notes at the time outstanding (as determined under the applicable Indenture), and then such waiver or consent shall be
effective only in the specific instance and for the specific purpose for which given. Upon the filing with the Collateral Agent of evidence of the consent of the Grantor and the Holders to any such amendment, waiver or consent as aforesaid, the
Collateral Agent shall join in the execution of such amendment, waiver or consent unless such amendment, waiver or consent affects the Collateral Agent’s own rights, duties or immunities under this Agreement, in which case, the Collateral Agent
may, in its discretion, but shall not be obligated to, execute such amendment, waiver or consent. No failure on the part of the Collateral Agent or any other Secured Party or the Grantor to exercise, and no delay in exercising any right hereunder,
shall operate as a waiver thereof; nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right. 
  
 Section 20. Notices, Etc. All notices and other communications provided for hereunder shall be either (i) in writing
(including telecopier or telex communication) and mailed, telecopied, telexed or otherwise delivered or (ii) by electronic mail (if electronic mail addresses 

  

 -24- 

 
are designated as provided below) confirmed immediately in writing, in the case of the Grantor or the Collateral Agent, addressed to it at its address set
forth opposite the Grantor’s or Collateral Agent’s name on the signature pages hereto or on the signature page to the Security Agreement Supplement pursuant to which it became a party hereto; or, as to any party, at such other address as
shall be designated by such party in a written notice to the other parties. All such notices and other communications shall, when mailed, telecopied, telexed, sent by electronic mail or otherwise, be effective when deposited in the mails,
telecopied, confirmed by telex answerback, sent by electronic mail and confirmed in writing, or otherwise delivered (or confirmed by a signed receipt), respectively, addressed as aforesaid; except that notices and other communications to the
Collateral Agent shall not be effective until received by the Collateral Agent. Delivery by telecopier of an executed counterpart of any amendment or waiver of any provision of this Agreement or of any Security Agreement Supplement or Schedule
hereto shall be effective as delivery of an original executed counterpart thereof. 
  
 Section 21. Continuing Security Interest. This Agreement shall create a continuing security interest in the Collateral and shall (a) remain in full force and effect until the earlier of (i) the satisfaction in
full of the applicable outstanding Notes and (ii) in the case of the 2009 Notes, the conversion of the entire outstanding principal amount of the 2009 Notes into Common Stock, (b) be binding upon the Grantor, its successors and assigns and (c)
inure, together with the rights and remedies of the Collateral Agent hereunder, to the benefit of the Secured Parties and their respective successors, transferees and assigns. 
  
 Section 22. Release; Termination. 
  
 (a) Upon any sale, lease, transfer or other disposition of any item of Collateral of the Grantor in
accordance with the terms of this Agreement (other than sales of Product Inventory in the ordinary course of business), the Collateral Agent will, at the Grantor’s expense, execute and deliver to the Grantor such documents as the Grantor shall
reasonably request to evidence the release of such item of Collateral from the assignment and security interest granted hereby; provided, however, that (i) at the time of such request and such release no Default or Event of Default
shall have occurred and be continuing, (ii) the Grantor shall have delivered to the Collateral Agent, at least ten Business Days prior to the date of the proposed release, a written request for release describing the item of Collateral and the terms
of the sale, lease, transfer or other disposition in reasonable detail, including, without limitation, the price thereof and any expenses in connection therewith, together with a form of release for execution by the Collateral Agent and a
certificate of the Grantor to the effect that the transaction is in compliance with the Indentures and this Agreement and as to such other matters as the Collateral Agent may request, (iii) the Grantor shall have delivered any opinions as required
under the Indentures and Section 314(d) of the Trust Indenture Act of 1939 and (iv) the proceeds of any such sale, lease, transfer or other disposition required to be applied, or any payment to be made in connection therewith, in accordance with the
Indentures shall, to the extent so required, be paid or made to, or in accordance with the instructions of, the Collateral Agent. 
  
 (b) Upon the latest of (i) the payment in full in cash of the Secured Obligations and (ii) the maturity date of the Notes in effect from
time to time, the pledge and security interest granted hereby shall automatically terminate and all rights to the Collateral shall revert to the Grantor. Upon any such termination, the Collateral Agent will, at the Grantor’s 

  

 -25- 

 
expense, execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination. 
  
 Section 23. Security Interest Absolute. The obligations of the Grantor
under this Agreement are independent of the Secured Obligations or any other Obligations of any other party under or in respect of the Indentures and the Notes, and a separate action or actions may be brought and prosecuted against the Grantor to
enforce this Agreement, irrespective of whether any action is brought against the Grantor under the Indentures or the Notes. All rights of the Collateral Agent and the other Secured Parties and the pledge, assignment and grant of a security interest
hereunder, and all obligations of the Grantor hereunder, shall be irrevocable, absolute and unconditional irrespective of, and the Grantor hereby irrevocably waives (to the maximum extent permitted by applicable law) any defenses it may now have or
may hereafter acquire in any way relating to, any or all of the following: 
  
 (a) any lack of validity or enforceability of either Indenture or any Note in effect from time to time, or any other agreement or instrument relating thereto; 
  
 (b) any change in the time, manner or place of payment of,
or in any other term of, all or any of the Secured Obligations or any other Obligations of the Grantor under or in respect of the Indentures and the Notes or any other amendment or waiver of or any consent to any departure from the Indentures or the
Notes, including, without limitation, any increase in the Secured Obligations resulting from the issuance of additional Notes to any Person; 
  
 (c) any taking, exchange, release or non-perfection of any Collateral or any other collateral, or any taking, release or amendment or
waiver of or consent to departure from any guaranty, for all or any of the Secured Obligations; 
  
 (d) any manner of application of any Collateral or any other collateral, or proceeds thereof, to all or any of the Secured Obligations, or
any manner of sale or other disposition of any Collateral or any other collateral for all or any of the Secured Obligations or any other Obligations of the Grantor under or in respect of the Indentures and the Notes or any other assets of the
Grantor; 
  
 (e) any change, restructuring or
termination of the corporate structure or existence of the Grantor; 
  
 (f) the failure of any other Person to execute this Agreement or any other agreement or the release or reduction of liability of the Grantor with respect to the Secured Obligations; or 
  
 (g) any other circumstance (including, without limitation,
any statute of limitations) or any existence of or reliance on any representation by any Secured Party that might otherwise constitute a defense available to, or a discharge of, the Grantor. 
  
 This Agreement shall continue to be effective or be reinstated, as the case may be, if at any
time any payment of any of the Secured Obligations is rescinded or must otherwise be returned by any Secured Party or by any other Person upon the insolvency, bankruptcy or reorganization of the Grantor or otherwise, all as though such payment had
not been made. 
  

 -26- 

 Section 24. Execution in Counterparts. This Agreement may be executed in any number of
counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by telecopier shall
be effective as delivery of an original executed counterpart of this Agreement. 
  
 Section 25. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. 
  
 Section 26. Jurisdiction, Etc. 
  
 (a) Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property,
to the nonexclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in New York City, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this
Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in any such New York
State court or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or
in any other manner provided by law. Nothing in this Agreement shall affect any right that any party may otherwise have to bring any action or proceeding relating to this Agreement in the courts of any jurisdiction. 
  
 (b) Each of the parties hereto irrevocably and
unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any New York
State or Federal court. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 
  
 Section 27. WAIVER OF JURY TRIAL. EACH OF THE GRANTOR AND EACH SECURED
PARTY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF THE SECURED PARTIES IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE OR ENFORCEMENT THEREOF. 
  
 [The remainder of this page intentionally left blank] 
  

 -27- 

 IN WITNESS WHEREOF, each of the Grantor and the Collateral Agent has caused this Agreement to be duly
executed and delivered by its officer thereunto duly authorized as of the date first above written. 
  

									
	 Address for Notices:
	 	 	 	GRANTOR
			
	 397 Eagleview Boulevard
 Exton, Pennsylvania 19341
 Fax: (610)
458-7380
 Attention: General Counsel
	 	 	 	  
 VIROPHARMA
INCORPORATED
  

	 	 	 	By	 	 /s/ Michel de Rosen

	 	 	 	 Title:
	 	 President and Chief Executive Officer

			
	 Address for Notices:
	 	 	 	COLLATERAL AGENT
			
	 One Federal Street, 3rd Floor
 Boston,
Massachusetts 02110
 Fax: (617) 603-6553
 Attention: Alison
Nadeau
	 	 	 	  
 U.S. BANK NATIONAL
ASSOCIATION
  

	 	 	 	By:	 	 /s/ Alison D.B. Nadeau

	 	 	 	 Title:
	 	 Vice President

  
 [signature page to
Security Agreement] 
  

  
 SCHEDULE I TO THE

 SECURITY AGREEMENT 
  
 CHIEF EXECUTIVE OFFICE, TYPE OF ORGANIZATION, JURISDICTION OF ORGANIZATION AND 
 ORGANIZATIONAL IDENTIFICATION NUMBER 
  

											
	 Grantor

	 	 Chief Executive Office

	 	 Place Where
Agreements are
Maintained

	 	 Type of
 Organization

	 	 Jurisdiction of
Organization

	 	 Organization
 I.D. No.

	ViroPharma Incorporated	 	 397 Eagleview
 Boulevard Exton,
 PA 19341
	 	 397 Eagleview
 Boulevard Exton,
 PA 19341
	 	Corporation	 	Delaware	 	2435760

  

  
 SCHEDULE II TO THE

 SECURITY AGREEMENT 
  
 PRODUCT AGREEMENTS AND ASSIGNED AGREEMENTS 
  

			
	 Grantor

	  	 Product Agreement

	ViroPharma Incorporated	  	Assignment, Transfer and Assumption Agreement, dated as of October 18, 2004 between the Grantor and Lilly
		
	ViroPharma Incorporated	  	Manufacturing Agreement, dated as of November 9, 2004, between the Grantor and Lilly
		
	ViroPharma Incorporated	  	Transition Services Agreement, dated as of November 9, 2004, between the Grantor and Lilly
		
	ViroPharma Incorporated	  	Cooperation Agreement, dated as of October 18, 2004, between the Grantor and Lilly
		
	ViroPharma Incorporated	  	Quality Agreement, dated as of November 9, 2004, between the Grantor and Lilly.
		
	 Grantor

	  	 Assigned Agreement

	ViroPharma Incorporated	  	Trademark Prior Rights Agreement, dated as of 09/01/61, between Lilly and Van Camp Sea Food Co.
		
	 	  	Trademark Prior Rights Agreement, dated as of 12/21/90, between Lilly and Imperial Chemical Industries Plc. (collectively, the “Prior Rights Agreements”)

  

  
 SCHEDULE III TO THE

 SECURITY AGREEMENT 
  
 DESCRIPTIONS & LOCATIONS OF PRODUCT EQUIPMENT AND PRODUCT INVENTORY 
  
 ViroPharma Incorporated 
  
 Product Equipment 
  
 None 
  
 Product Inventory 
  
 A.
Description: Approximately [***] of Polyethylene glycol, otherwise known as “PEG,” which is purchased by Grantor from Lilly pursuant to the Transfer Agreement 
  
 B. Location: Lilly Corporate Center, Indianapolis, IN 46285* 
  

	*	Subject to Bailee Subordination 

  

	[***]	INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  

  
 SCHEDULE IV TO THE

 SECURITY AGREEMENT 
  
 CHANGES IN NAME, LOCATION, ETC. 
  
 Changes in the Grantor’s Name (including new grantor with a new name and names associated with all predecessors in interest of the Grantor) 

 
 None 
  
 Changes in the Grantor’s Chief Executive Office 
  
 On July 19, 2004, the Grantor moved from 405 Eagleview Boulevard, Exton, PA 19341 to its current location 
  
 Changes in the Location of Product Equipment and Product Inventory 

 
 None 
  
 Changes in the Type of Organization 
  

None 
  
 Changes in the Jurisdiction of Organization 
  
 None

  
 Changes in the Organizational Identification Number 

 
 None 
  

  
 SCHEDULE V TO THE

 SECURITY AGREEMENT 
  
 INTELLECTUAL PROPERTY 
  
 I. Product Patents 
  

													
	 Grantor

	  	 Patent Titles

	  	 Country

	  	 Patent No.

	  	 Applic. No.

	  	 Filing Date

	  	 Issue Date

	ViroPharma Incorporated	  	 Vancomycin-HCL
 Solutions and Lyophilization Thereof
	  	United States	  	4,885,275	  	07/109,885	  	10/15/87	  	12/05/89
	ViroPharma Incorporated	  	Vancomycin Precipitation Process	  	United States	  	5,037,652	  	07/315,751	  	02/27/89	  	08/06/91
	ViroPharma Incorporated	  	Chromatographic Purification Process*	  	United States	  	4,874,843	  	07/128,351	  	12/03/87	  	10/17/89
	ViroPharma Incorporated	  	Glycopeptide Recovery Process*	  	United States	  	4,845,194	  	07/019,914	  	02/27/87	  	07/04/89

  

	*	Patents are licensed from Lilly and are not Purchased Patents. 

  
 II. Product Trademarks & Trade Dress 
  

											
	 Grantor

	 	 Trademark/
 Trade Dress

	 	 Country

	 	 Mark

	 	 Reg. No.

	 	 Registration Date

	ViroPharma Incorporated	 	Vancocin (vancomycin hydrochloride)	 	United States	 	VANCOCIN	 	683928	 	08/25/59
	ViroPharma Incorporated	 	Pulvules*	 	United States	 	 	 	144210	 	 
	ViroPharma Incorporated	 	Parabaloidal Capsule*	 	United States	 	 	 	732393	 	 

  

	*	Trademarks/Trade Dress are licensed from Lilly and are not Purchased Trademarks. 

  
 III. Domain Names 
  
 All internet domain names, and the registrations therefore, that are comprised, in whole or in part, of the Trademarks, including, without limitation the following:

  
 Vancocin.us 
  
 Vancomycin.net 
  
 Vancomycin.org 
  
 V. Product Copyrights 
  

															
	 Grantor

	 	 Title of Work

	 	 Country

	 	 Title

	 	 Reg. No.

	 	 Applic. No.

	 	 Filing Date

	 	 Issue Date

	 	 	None	 	 	 	 	 	 	 	 	 	 	 	 

  

 VI. Product IP Agreements 
  

			
	 Grantor

	  	 IP Agreements

	 ViroPharma Incorporated
	  	Assignment, Transfer and Assumption Agreement, dated as of October 18, 2004, between the Grantor and Lilly

  
 VII. ViroPharma Incorporated
Registered Product Trademarks 
  

							
	 Trademark

	 	 Country

	 	 Reg. No.

	 	 Registration Date

	 VIROPHARMA INCORPORATED
 (w/design)
	 	United States	 	2373217	 	8/1/2000
				
	VIROPHARMA	 	United States	 	2373218	 	8/1/2000
				
	VIROPHARMA	 	United States	 	2459907	 	6/12/2001
				
	 VIROPHARMA INCORPORATED
 (w/design)
	 	United States	 	2457511	 	6/15/2001

  
 To the best of Grantor’s
knowledge, no Person is engaging in any activity that infringes, misappropriates, dilutes, misuses or otherwise violates the Product Intellectual Property Collateral or the Grantor’s rights in or use thereof in a manner that would have a
material adverse effect on the Grantor except that: 
  
 Lilly informed Grantor
that Lilly is aware that Marketed Product is offered for sale on internet web sites and that unauthorized re-importation or importation into the Territory of Marketed Products may have occurred and may be occurring but that such quantities, to
Lilly’s knowledge, are not material. Lilly informed Grantor that Lilly is not aware of importation of any corresponding infringing or gray market goods, except as may be indicated by the offer for sale of Marketed Product on internet web sites.

  
 Lilly informed Grantor that it is aware that the domain name
“VANCOCIN.COM” has been registered by Thao Spriet, 95 Beaverwood Dr., Hill City, Kansas 67642. Lilly has not licensed this use of the Vancocin trademark, or taken any other action with respect to this issue. 
  

  
 SCHEDULE VI TO THE

 SECURITY AGREEMENT 
  
 BOOKS AND RECORDS 
  
 All regulatory files related to the Marketed Product, including correspondence with DDMAC. 
  
 All archived scripts and FAQs used by Lilly in connection with customer and physician inquiries and complaints in the course of performing
the Activities (as defined in the Transfer Agreement). 
  

  
 SCHEDULE VII TO THE

 SECURITY AGREEMENT 
  
 NEW DRUG APPLICATIONS, ABBREVIATED NEW 
 DRUG APPLICATIONS & INVESTIGATIONAL NEW DRUG APPLICATIONS 
  
 Discontinued Product ANDAs 
  

					
	 Grantor

	  	 ANDA No.

	  	 Description

			
	 Grantor
	  	61-667	  	Oral Solution
			
	 Grantor
	  	60-180	  	IV
			
	 Grantor
	  	62-476	  	IV
			
	 Grantor
	  	62-716	  	IV (ADD-VANTAGE)*
			
	 Grantor
	  	62-812	  	IV
			
	 Grantor
	  	23,016 (IND)	  	IV

  
 Marketed Product
NDAs 
  

					
	 Grantor

	  	 NDA No.

	  	 Description

	 Grantor
	  	50-606	  	Oral Capsules

  

	*	In order to use this ANDA a license to the [***] from [***] is required. 

  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

  
 SCHEDULE VIII TO THE

 SECURITY AGREEMENT 
  
 PRODUCT DEPOSIT ACCOUNT 
  

							
	 Grantor

	  	 Name of Account

	  	 Name and Address of
Pledged Account Bank

	  	 Account Number

	 ViroPharma Incorporated
	  	deposit account	  	Comerica Bank	  	[***]

  

	[***] 	INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  

  
 SCHEDULE IX TO THE

 SECURITY AGREEMENT 
  
 COMMERCIAL TORT CLAIMS 
  
 None. 
  

  
 EXHIBIT A TO THE

 SECURITY AGREEMENT 
  
 FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT 
  
 This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, amended and restated, supplemented or otherwise modified from time to time, this “IP Security
Agreement”) dated [            ], 2004, is made by ViroPharma Incorporated, a Delaware corporation (the “Grantor”) in favor of [U.S. Bank National Association],
as collateral agent (the “Collateral Agent”) for the Secured Parties (as defined in the Security Agreement referred to below). 
  
 WHEREAS, the Grantor has entered into an Indenture dated as of October 18, 2004 (as amended, amended and restated, supplemented or otherwise modified from time to time,
the “Bridge Indenture”), with US Bank National Association, as Trustee, pursuant to which the Grantor has authorized the issuance of 10% Senior Secured Bridge Notes due 2005 (the “Bridge Notes”). Upon the fulfillment of certain
conditions set forth in the Bridge Indenture, the Bridge Notes shall automatically be exchanged for Grantor’s 6% Convertible Senior Secured Notes due 2009 (as they may hereafter be amended, amended and restated, supplemented, or otherwise
modified from time to time, the “2009 Notes,” and together with the Bridge Notes, collectively, the “Notes”) issued pursuant to an Indenture entered into between Grantor and Trustee, dated as of October 18, 2004 (as it may
hereafter be amended, amended and restated, supplemented, or otherwise modified from time to time, the “2009 Indenture,” and together with the Bridge Indenture, each an “Indenture” and collectively the “Indentures”).
Terms defined in the Indentures and the Security Agreement (as defined herein) and not otherwise defined herein are used herein as defined in the Indentures and the Security Agreement. 
  
 WHEREAS, the Grantor has executed and delivered that certain Security Agreement dated November 9, 2004 made by the Grantor to the Collateral
Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”). 
  
 WHEREAS, under the terms of the Security Agreement, the Grantor has granted to the Collateral Agent, for the ratable benefit of the Secured Parties, a security interest
in, among other property, certain intellectual property of the Grantor, and has agreed as a condition thereof to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office, the United States Copyright Office and other
governmental authorities. 
  
 NOW, THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees as follows: 
  
 1. Grant of Security. The Grantor hereby grants to the Collateral Agent for the ratable benefit of the Secured Parties a security interest in all of the Grantor’s right, title and interest in and to the
following (the “Collateral”): 
  
 a.
the patents and patent applications set forth in Schedule A hereto, together with all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations thereof (the “Patents”); 
  
 b. the trademark and service mark registrations and
applications set forth in Schedule B hereto and all renewals thereof (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a
security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law), together with the goodwill symbolized thereby (the “Trademarks”); 
  
 c. all copyrights, whether registered or unregistered, now
owned or hereafter acquired by the Grantor, including, without limitation, the copyright registrations and applications and exclusive copyright licenses, as set forth in Schedule C hereto (the “Copyrights”); 
  

 d. all other rights in the foregoing of any kind whatsoever of the Grantor accruing
thereunder or pertaining thereto; 
  
 e. any and
all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or
otherwise recover, such damages; and 
  
 f. any
and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing. 
  
 2. Security for Obligations. The grant of a security interest in, the
Collateral by the Grantor under this IP Security Agreement secures the payment of all Obligations of the Grantor now or hereafter existing under or in respect of the Indentures and the Notes, whether direct or indirect, absolute or contingent, and
whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. 
  
 3. Recordation. The Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and
the Commissioner for Trademarks and any other applicable government officer record this IP Security Agreement. 
  
 4. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be
deemed to be an original and all of which taken together shall constitute one and the same agreement. 
  
 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. The
Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and
provisions of which are incorporated herein by reference as if fully set forth herein. 
  
 6. Governing Law. This IP Security Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. 
  
 IN WITNESS WHEREOF, the Grantor has caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly
authorized as of the date first above written. 
  

			
	VIROPHARMA INCORPORATED
		
	By	 	 
	 Name:
	 	 
	 Title:
	 	 
	
	Address for Notices:
397 Eagleview Boulevard
Exton, Pennsylvania 19341
Fax: (610) 458-7380
Attention: General Counsel

  
 EXHIBIT B TO THE

 SECURITY AGREEMENT 
  
 FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT 
  
 This INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT (this “IP Security Agreement Supplement”) dated
[                    ], 2004, is made by ViroPharma Incorporated, a Delaware corporation (the “Grantor”), in favor of [U.S. Bank
National Association], as collateral agent (the “Collateral Agent”) for the Secured Parties (as defined in the Security Agreement referred to below). 
  

WHEREAS, the Grantor has entered into an Indenture dated as of October 18, 2004 (as amended, amended and restated, supplemented or otherwise modified from time to
time, the “Bridge Indenture”), with US Bank National Association, as Trustee, pursuant to which the Grantor has authorized the issuance of 10% Senior Secured Bridge Notes due 2005 (the “Bridge Notes”). Upon the fulfillment of
certain conditions set forth in the Bridge Indenture, the Bridge Notes shall automatically be exchanged for Grantor’s 6% Convertible Senior Secured Notes due 2009 (as they may hereafter be amended, amended and restated, supplemented, or
otherwise modified from time to time, the “2009 Notes,” and together with the Bridge Notes, collectively, the “Notes”) issued pursuant to an Indenture entered into between Grantor and Trustee, dated as of October 18, 2004 (as it
may hereafter be amended, amended and restated, supplemented, or otherwise modified from time to time, the “2009 Indenture,” and together with the Bridge Indenture, each an “Indenture” and collectively the
“Indentures”). Terms defined in the Indentures and the Security Agreement (as defined herein) and not otherwise defined herein are used herein as defined in the Indentures and the Security Agreement. 
  
 WHEREAS, the Grantor has executed and delivered that certain Security Agreement dated
November 9, 2004 made by the Grantor to the Collateral Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) and that certain Intellectual Property Security Agreement dated
November 9, 2004 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”). 
  
 WHEREAS, under the terms of the Security Agreement, the Grantor has granted to the Collateral Agent, for the ratable benefit of the Secured Parties, a security interest
in the Collateral and has agreed as a condition thereof to execute this IP Security Agreement Supplement for recording with the U.S. Patent and Trademark Office, the United States Copyright Office and other governmental authorities. 
  
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Grantor agrees as follows: 
  
 1.
Grant of Security. The Grantor hereby grants to the Collateral Agent, for the ratable benefit of the Secured Parties, a security interest in all of the Grantor’s right, title and interest in and to the following (the “Additional
Collateral”): 
  
 a. the patents and patent
applications set forth in Schedule A hereto, together with all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations thereof (the “Patents”); 
  
 b. the trademark and service mark registrations and
applications set forth in Schedule B hereto and all renewals thereof (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a
security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law), together with the goodwill symbolized thereby (the “Trademarks”); 
  
 c. the copyright registrations and applications and
exclusive copyright licenses set forth in Schedule C hereto (the “Copyrights”); 

 d. all other rights in the foregoing of any kind whatsoever of the Grantor accruing
thereunder or pertaining thereto; 
  
 e. all any
and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect,
or otherwise recover, such damages; and 
  
 f.
any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the foregoing or arising from any of the foregoing. 
  
 2. Supplement to Security Agreement. Schedule V to the Security
Agreement is, effective as of the date hereof, hereby supplemented to add to such Schedule the Additional Collateral. 
  
 3. Security for Obligations. The grant of a security interest in the Additional Collateral by the Grantor under this IP Security Agreement
Supplement secures the payment of all Obligations of the Grantor now or hereafter existing under or in respect of the Indentures and the Notes, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations,
interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. 
  
 4. Recordation. The Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for
Trademarks and any other applicable government officer to record this IP Security Agreement Supplement. 
  
 5. Grants, Rights and Remedies. This IP Security Agreement Supplement has been entered into in conjunction with the provisions of the Security
Agreement. The Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Additional Collateral are more fully set forth in the Security
Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. 
  
 6. Governing Law. This IP Security Agreement Supplement shall be governed by, and construed in accordance with, the laws of the State of New York.

  
 IN WITNESS WHEREOF, the Grantor has caused this IP Security Agreement
Supplement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written. 
  

			
	VIROPHARMA INCORPORATED
		
	By	 	 
	 	 	 Name:

	 	 	 Title:

	
	Address for Notices:
397 Eagleview Boulevard
Exton, Pennsylvania 19341
Fax: (610) 458-7380
Attention: General Counsel

  
 EXHIBIT C TO THE

 SECURITY AGREEMENT 
  
 FORM OF NDA TRANSFER LETTER 
  
 (VIROPHARMA INCORPORATED LETTERHEAD) 
  
 [Date] 
  
 [Food and Drug Administration 
 1390 Piccard Drive 
 Rockville, MD 20850] 
  

	 	Re:	Transfer of Ownership 

 New Drug Application NDA
[                    ], NDA No. [            ] 
  
 To Whom It May Concern: 
  
 We are hereby informing you, in accordance with Section 505 of the Federal Food, Drug and Cosmetic Act, and 21 C.F.R. §
314.72, that as of the date of this letter, all rights to the New Drug Application described below (the “NDA”), which prior to such date was officially owned and held by ViroPharma Incorporated, have been transferred to: 
                                       
                                        
                                        
                                        
                                        
                                        
                    
 (the “Transferee”) and that
such Transferee is the new official owner and responsible party for the following NDA: 
  
 NDA [                ]
(                                    ) and any supplements and
amendments thereto (see attached list). 
  
 In accordance with 21
C.F.R. §314.72, the Transferee has received from ViroPharma Incorporated a complete copy of the above-referenced NDA and any supplements, amendments, and records required to be kept under 21 C.F.R. § 314.81. 
  
 Should any questions arise in connection with the above, please do not
hesitate to contact me. 
  

			
	Sincerely,
	
	 VIROPHARMA INCORPORATED

		
	By:	 	 
	 Title:
	 	 

  
 ATTACHMENT TO VIROPHARMA
INCORPORATED 
 OWNERSHIP TRANSFER OF NDA 
  
 [                                      
              ] 

  
 EXHIBIT D TO THE

 SECURITY AGREEMENT 
  
 FORM OF DEPOSIT ACCOUNT CONTROL AGREEMENT 
  
 This Deposit Account Control Agreement dated as of
                    , 2004 (this “Agreement”) among ViroPharma Incorporated, a Delaware corporation (the “Debtor”), U.S.
Bank National Association, as collateral agent for the Secured Parties (the “Collateral Agent”) and                     , (the
“Financial Institution”). Capitalized terms used but not defined herein shall have the meaning assigned thereto or by reference thereto in the Security Agreement dated
                    , 2004, between the Debtor and the Collateral Agent (as it may be amended, restated or modified from time to time, the
“Security Agreement”). All references herein to the “UCC” means the Uniform Commercial Code as in effect in the State of New York. 
  
 1. Establishment of Deposit Account. The Financial Institution hereby confirms and agrees that: 
  
 a. The Financial Institution has established account number
[IDENTIFY ACCOUNT NUMBER] in the name “[IDENTIFY EXACT TITLE OF ACCOUNT]” (such account and any successor account, the “Deposit Account”) and the Financial Institution shall not change the name or account number of the Deposit
Account without the prior written consent of the Collateral Agent. 
  
 b. The Financial Institution is a “bank” as defined in Section 9-102 (a)(8) of Article 9 of the UCC. The Deposit Account is a “deposit account” as defined in Section 9-102(a)(29) of Article 9 of
the UCC. 
  
 2. Control of the Deposit Account. If at any
time the Financial Institution shall receive any written instructions originated by the Collateral Agent directing the disposition of funds in the Deposit Account, the Financial Institution shall comply with such instructions without further consent
by the Debtor or any other person. The Financial Institution may also comply with instructions directing the disposition of funds in the Deposit Account originated by Debtor or its authorized representatives until such time as the Collateral Agent
delivers a written notice to Financial Institution that the Collateral Agent is thereby exercising exclusive control over the Deposit Account. Such notice is referred to herein as the “Notice of Exclusive Control.” After Financial
Institution receives a Notice of Exclusive Control, it will cease complying with instructions concerning the Deposit Account or funds on deposit therein originated by Debtor or its representatives. 
  
 3. Subordination of Lien; Waiver of Set-Off. In the event that the
Financial Institution has or subsequently obtains by agreement, by operation of law or otherwise a security interest in the Deposit Account or any funds credited thereto, the Financial Institution hereby agrees that such security interest shall be
subordinate to the security interest of the Collateral Agent. Money and other items credited to the Deposit Account will not be subject to deduction, set-off, banker’s lien, or any other right in favor of any person other than the Collateral
Agent (except that the Financial Institution may set off (a) all amounts due to the Financial Institution in respect of customary fees and expenses for the routine maintenance and operation of the Deposit Account and (b) the face amount of any
checks that have been credited to such Deposit Account but are subsequently returned unpaid because of uncollected or insufficient funds). 
  
 4. Choice of Law. This Agreement and the Deposit Account shall each be governed by the laws of the State of New York. Regardless of any provision
in any other agreement, for purposes of the UCC, New York shall be deemed to be the Financial Institution’s jurisdiction (within the meaning of Section 9-304 of Article 9 of the UCC) and the Deposit Account shall be governed by the laws of the
State of New York. 
  
 5. Conflict with Other Agreements.

  
 a. In the event of any conflict between this
Agreement (or any portion thereof) and any other agreement now existing or hereafter entered into, the terms of this Agreement shall prevail (including without limitation, any other agreement referred to in the second sentence of Section 4 hereof).

 b. No amendment or modification of this Agreement or waiver of any provision hereof shall
be binding on any party hereto unless it is in writing and is signed by all of the parties hereto. 
  
 c. The Financial Institution hereby confirms and agrees that: 
  
 i. There are no other agreements entered into between the Financial Institution and the Debtor with respect
to the Deposit Account; and 
  
 ii. It has not
entered into, and until the termination of this Agreement, will not enter into, any agreement with any other person relating to the Deposit Account and/or any funds credited thereto pursuant to which it has agreed to comply with instructions
originated by such person as contemplated by Section 9-104 of Article 9 of the UCC. 
  
 6. Adverse Claims. The Financial Institution does not know of any Liens, claims or encumbrances relating to the Deposit Account. If any person asserts any lien, encumbrance or adverse claim (including any writ,
garnishment, judgment, warrant of attachment, execution or similar process) against the Deposit Account, the Financial Institution will promptly notify the Collateral Agent and the Debtor thereof. 
  
 7. Maintenance of Deposit Account. In addition to, and not in lieu of,
the obligation of the Financial Institution to honor instructions as set forth in Section 2 hereof, the Financial Institution agrees to maintain the Deposit Account as follows: 
  
 a. Statements and Confirmations. The Financial Institution will promptly send copies of all
statements, confirmations and other correspondence concerning the Deposit Account simultaneously to each of the Debtor and the Collateral Agent at the address for each set forth in Section 11 of this Agreement. 
  
 b. Tax Reporting. All interest, if any, relating to
the Deposit Account, shall be reported to the Internal Revenue Service and all state and local taxing authorities under the name and taxpayer identification number of the Debtor. 
  
 8. Representations, Warranties and Covenants of the Financial Institution. The Financial Institution hereby makes the
following representations, warranties and covenants: 
  
 a. The Deposit Account has been established as set forth in Section 1 and such Deposit Account will be maintained in the manner set forth herein until termination of this Agreement. 
  
 b. This Agreement is the valid and legally binding
obligation of the Financial Institution. 
  
 9. Indemnification
of Financial Institution. The Debtor and the Collateral Agent hereby agree that the Debtor, its successors and assigns shall at all times indemnify and save harmless the Financial Institution from and against any and all claims, actions and
suits of others arising out of the terms of this Agreement or the compliance of the Financial Institution with the terms hereof, except to the extent that such arises from the Financial Institution’s gross negligence or willful misconduct, and
from and against any and all liabilities, losses, damages, costs, charges, reasonable counsel fees and other expenses of every nature and character arising by reason of the same, until the termination of this Agreement. 
  
 10. Successors; Assignment. The terms of this Agreement shall be
binding upon, and shall inure to the benefit of, the parties hereto and their respective successors or heirs and personal representatives who obtain such rights solely by operation of law. The Collateral Agent may assign its rights hereunder only
with the express written consent of the Financial Institution and by sending written notice of such assignment to the Debtor. 
  
 11. Notices. Any notice, request or other communication required or permitted to be given under this Agreement shall be in writing and deemed to
have been properly given when delivered in person, or when sent by telecopy or other electronic means and electronic confirmation of error free receipt is received or two (2) days after 

 
being sent by certified or registered United States mail, return receipt requested, postage prepaid, addressed to the party at the address set forth below.

  

			
	Debtor:	  	ViroPharma Incorporated
	 	  	397 Eagleview Boulevard
	 	  	Exton, Pennsylvania 19341
	 	  	Attention: General Counsel
	 	  	Telecopier: 610-458-7380
		
	Collateral Agent:	  	U.S. Bank, National Association
	 	  	One Federal Street, 3rd Floor
	 	  	Boston, Massachusetts 02110
	 	  	Attention: Alison Nadeau
	 	  	Telecopier: (617) 603-6553
		
	Financial Institution:	  	[Name]
	 	  	[Address]
	 	  	Attention:
	 	  	Telecopier:

  
 Any party may change its address for
notices in the manner set forth above. 
  
 12. Termination;
Survival. 
  
 a. The Collateral Agent may
terminate this Agreement by notice to the Financial Institution and the Debtor. If the Collateral Agent notifies the Financial Institution that it has released its security interest in the Deposit Account, this Agreement will immediately terminate.

  
 b. The Financial Institution may terminate
this Agreement on 60 days’ prior notice to the Collateral Agent and the Debtor, provided that before such termination the Financial Institution and the Debtor shall make arrangements to transfer the property credited to the Deposit
Account to another Financial Institution that shall have executed, together with the Debtor, a deposit account control agreement in favor of the Collateral Agent in respect of such property in substantially the form of this Agreement or otherwise in
form and substance reasonably satisfactory to the Collateral Agent. 
  
 13. Counterparts. This Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Agreement by signing and delivering one or more
counterparts. 

 IN WITNESS WHEREOF, the parties hereto have caused this Deposit Account Control Agreement to be executed
as of the date first above written by their respective officers thereunto duly authorized. 
  

			
	 VIROPHARMA INCORPORATED

		
	By:	 	 
	 	 	 Name:

	 	 	 Title:

	
	U.S. BANK NATIONAL ASSOCIATION,
as Collateral Agent
		
	By:	 	 
	 	 	 Name:

	 	 	 Title:

	
	[NAME OF INSTITUTION SERVING AS FINANCIAL INSTITUTION]
		
	By:	 	 
	 	 	 Name:

	 	 	 Title:Cooperation Agreement

  
 Exhibit 10.4

  
 EXECUTION COPY 
  
 Cooperation Agreement 
  
 THIS COOPERATION AGREEMENT (this “Agreement”), is entered
into this 18th day of October, 2004 (the “Effective Date”) by and between ViroPharma
Incorporated (“ViroPharma”), a corporation organized and existing under the laws of the State of Delaware with offices located at 397 Eagleview Boulevard, Exton, PA 19341 and Eli Lilly and Company
(“Lilly”), a corporation organized and existing under the laws of the State of Indiana with offices located at Lilly Corporate Center, Indianapolis, Indiana 46285. ViroPharma and Lilly are sometimes referred to herein individually
as a “Party” and collectively as “Parties”. 
  
 In consideration of the mutual covenants and agreements set forth in this Agreement, the Parties agree as follows: 
  
 1. Explanatory Statement and Definitions. 
  
 (a) Background. Lilly and ViroPharma have entered into an Assignment, Transfer and Assumption Agreement dated of even date herewith (the
“Assignment Agreement”) pursuant to which ViroPharma has, among other things, agreed to purchase from Lilly the United States rights to the Marketed Product. Lilly currently manufactures the Marketed Product and, pursuant to the
Manufacturing Agreement to be entered into on the Closing Date (the “Manufacturing Agreement”), Lilly will agree to manufacture the Marketed Product for ViroPharma for the period of time and in accordance with the terms and
conditions set forth in the Manufacturing Agreement. Any capitalized terms not otherwise defined in this Agreement shall have the meanings assigned to such terms in the Assignment Agreement or in the Manufacturing Agreement. Lilly will cease being a
manufacturer of the Marketed Product and is in the process of establishing the Third Person Supply Chain (“TPSC”) with the goal of providing to ViroPharma a manufacturing operation to take Lilly’s place. The TPSC comprises (a)
the purchase of bulk API from [***]. pursuant to the Bulk Material Supply Agreement between Lilly and [***] dated October 12, 2004 (the “API Supply Agreement”) and (b) the purchase of finished Marketed Product from [***] pursuant to
(i) the Master Agreement between Lilly and [***] dated March 13, 2003, as amended by that certain Amendment No. 1 to the Master Agreement dated September 21, 2004 and effective August 31, 2004 (as amended, the “[***] Master
Agreement”) and (ii) the Project Agreement between Lilly and [***] dated September 21, 2004 and effective August 31, 2004 (the “[***] Project Agreement,” and, together with the [***] Master Agreement, the “Finished
Product Supply Agreement”). The API Supply Agreement and the Finished Product Supply Agreement are, collectively, the “TPSC Agreements.” Lilly has provided to ViroPharma complete and accurate copies of the TPSC Agreements, and
there are no other written agreements or material oral understandings relating to the TPSC. Any reference to an assignment of the [***] Master Agreement means that both Lilly and ViroPharma will be able to operate under the [***] Master Agreement as
if there were two separate identical [***] Master Agreements related to each of Lilly’s and Viropharma’s respective products as set forth in the confirmation attached hereto as Exhibit A. 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 (b) Roadmap. Among other provisions, Section 2.3 of the Manufacturing Agreement and Section 13.3
of the Assignment Agreement (collectively, the “TPSC Provisions”) address the migration from Lilly to the TPSC for the manufacture of the Marketed Product, and Lilly’s delivery of the TPSC to ViroPharma. Pursuant to the TPSC
Provisions, the parties have agreed that Lilly will assist ViroPharma in entering into its own agreements with [***] and, failing that, take an assignment of the API Supply Agreement and/or the Finished Product Supply Agreement from Lilly (the
“TPSC Hand-Off”). The purpose of this Agreement is to assist the Parties in implementing the TPSC Hand-Off, including: (i) Lilly’s covenant to help ViroPharma enter into its own agreements; (ii) in the alternative, Lilly’s
covenant to assign the agreements to ViroPharma; (iii) certain understandings regarding product development and qualification regardless of the form of the TPSC Hand-Off; (iv) certain understandings regarding the TPSC Agreements prior to the TPSC
Hand-Off; (v) certain understandings regarding ViroPharma’s involvement in the development function; and (vi) certain understandings regarding Lilly’s preparation of regulatory materials for filing by ViroPharma. To the extent that there
is any conflict between the TPSC Provisions and this Agreement, the provisions of this Agreement shall control. 
  
 2. TPSC Agreements for ViroPharma. 
  
 (a) API Supply Agreement. 
  
 (i) Promptly following the Closing Date, Lilly shall assist ViroPharma in negotiating an agreement with [***] for the supply of bulk API
used to manufacture the Marketed Product in the Territory in form substantially similar to the API Supply Agreement, with any changes thereto to be approved by ViroPharma in its sole discretion. In the event that such an agreement has not been
entered into, Lilly shall assign the API Supply Agreement to ViroPharma, together with the Quality Agreement described therein and all other agreements related thereto, and the timing of such assignment will be at Lilly’s discretion upon
reasonable notice to ViroPharma but will occur no earlier than after the Third Person Supply Chain has all necessary Regulatory Approvals for the manufacture and supply of Marketed Product and no later than the end of the Contract Period (as defined
in Section 8.1 of the Manufacturing Agreement) of the Manufacturing Agreement; provided that following such assignment, Lilly shall remain obligated for any liabilities or obligations arising under the TPSC Agreements prior to the assignment.

  
 (ii) In the event that the TPSC Hand-Off
takes the form of an assignment, then Lilly shall use commercially reasonable efforts to enter into an agreement directly with [***] for the supply of [***] (including, for purposes hereof, agreeing with [***] to make such purchases by means of
[***] purchase orders). If Lilly is unable to enter into an agreement with [***] or otherwise obtain a supply of [***] needed for the manufacture of its product for Canada, if requested by Lilly, ViroPharma will make commercially reasonable efforts
to obtain a sufficient quantity of [***} to supply to [***] or any other manufacturer of finished Marketed Product to allow such manufacturer to meet Lilly’s requirements of finished product for Canada. In such event, Lilly will provide
ViroPharma with an appropriate forecast and order for such purpose as set forth in Sections 13 and 14 of the API Supply Agreement and Lilly will 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 Page 2 of 10 

 
pay ViroPharma in a time frame that permits ViroPharma to remain current on all of its payment obligations to [***] with respect to such product. In the
event Lilly requests that ViroPharma supply [***] to meet Lilly’s requirements for bulk material for use in manufacturing its product for Canada, ViroPharma’s sole obligation will be to place such order with [***] for delivery to Lilly,
and ViroPharma shall have no obligation, and Lilly shall hold ViroPharma harmless, with respect to any claims Lilly may have with respect to the manufacture, supply (including any allocation of limited supply made by ViroPharma), quality, delivery
or other aspects of [***] performance with respect thereto. 
  
 (b) Finished Product Supply Agreement. 
  
 (i) Promptly following the Closing Date, Lilly shall assist ViroPharma in negotiating an agreement with [***] for the supply of finished Marketed Product in the Territory in form substantially similar to the Finished Product Supply
Agreement, with any changes thereto to be approved by ViroPharma in its sole discretion, which agreement shall provide for supply of Marketed Product to ViroPharma at the end of the term of the Manufacturing Agreement. In the event that such an
agreement has not been entered into, Lilly shall assign the Finished Product Supply Agreement to ViroPharma, together with the Quality Agreement described therein and all other agreements related thereto, and the timing of such assignment will be at
Lilly’s discretion upon reasonable notice to ViroPharma but will occur no earlier than after the Third Person Supply Chain has all necessary Regulatory Approvals for the manufacture and supply of Marketed Product and no later than the end of
the Contract Period (as defined in Section 8.1 of the Manufacturing Agreement) of the Manufacturing Agreement; provided that following such assignment, Lilly shall remain obligated for any liabilities or obligations arising under the TPSC Agreements
prior to the assignment. 
  
 (ii) In the event
that the TPSC Hand-Off takes the form of an assignment, then Lilly shall use commercially reasonable efforts to enter into an agreement directly with [***] for the supply of finished product. If Lilly is unable to enter into an agreement with [***]
or otherwise obtain a supply of finished product needed for the manufacture of its product for Canada, if requested by Lilly, ViroPharma will make commercially reasonable efforts to obtain a sufficient quantity of finished product from [***] to
allow such manufacturer to meet Lilly’s requirements of finished product for Canada. In such event, Lilly will provide ViroPharma with an appropriate forecast and order for such purpose as set forth in the Finished Product Supply Agreement and
Lilly will pay ViroPharma in a time frame that permits ViroPharma to remain current on all of its payment obligations to [***] with respect to such product. In the event Lilly requests that ViroPharma supply finished product to meet Lilly’s
requirements for Canada, ViroPharma’s sole obligation will be to place such order with [***] for delivery to Lilly, and ViroPharma shall have no obligation, and Lilly shall hold ViroPharma harmless, with respect to any claims Lilly may have
with respect to the manufacture, supply (including any allocation of limited supply made by 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 Page 3 of 10 

 
ViroPharma), quality, delivery or other aspects of [***] performance with respect thereto. 
  
 (c) Timing. The Parties will diligently pursue the negotiation of the agreements referred to in
Section 2(a) and (b) and attempt to finalize such agreements as soon as reasonably possible after the Closing Date. 
  
 (d) Certain Understandings. Notwithstanding any provision in this Agreement to the contrary: (i) subject to paragraph 8 of this
Agreement, all responsibilities and obligations of Lilly set forth in the TPSC Agreements relating to the development of and obtaining of marketing approval for the Marketed Product, including out of pocket expenses and technology transfer
obligations, shall remain the responsibilities and obligations of Lilly regardless of the occurrence or form of the TPSC Hand-Off; (ii) as of the Closing Date, all technology transfer relating to Lilly’s manufacturing processes shall be deemed
to be sublicensed by [***], as the case may be, from ViroPharma, pursuant to the exclusive license granted by Lilly to ViroPharma under the Licensed Technology in the Assignment Agreement, and any data and intellectual property created by Lilly
and/or [***] in the context of implementing the TPSC shall automatically become part of the Licensed Technology; (iii) Lilly shall deliver final copies of all technology transfer documentation to ViroPharma promptly after delivery to [***], but in
any event no later than 30 days after delivery to [***]; (iv) Lilly shall not amend the TPSC Agreements, or take any actions permitted or contemplated thereunder of a material nature, without the express prior written consent of ViroPharma, and
without limiting the generality of the foregoing, any actions identified in Sections 4 and 5 below as requiring the participation of Lilly under such circumstances shall, for the purposes of this section, require the consent of ViroPharma; (v)
beginning on the Closing Date, Lilly shall invite ViroPharma to be part of all material pre-scheduled discussions with [***], including scheduled weekly conference calls, and shall provide to ViroPharma copies of all material correspondence and
Lilly shall update ViroPharma as soon as reasonably practicable on any material pre-scheduled discussion or other non-scheduled material discussion that ViroPharma is unable or does not participate in; (vi) Lilly shall timely prepare and enable
ViroPharma to make timely submissions of all necessary regulatory filings to obtain marketing approval of the Marketed Product manufactured by the TPSC as contemplated in the TPSC Agreements; and (viii) except for information rights and covenants
relating to refrain from changing the TPSC Agreements, ViroPharma’s other rights set forth in this Agreement shall not become effective until the Closing Date. 
  
 (e) Cooperation. If for any reason the TPSC Hand-Off is ineffective or adversely affects the rights
of ViroPharma so that ViroPharma would not in fact receive all necessary rights under the TPSC Agreements, Lilly and ViroPharma will cooperate in a mutually agreeable arrangement under which Lilly would obtain any benefits not received by ViroPharma
in the TPSC Hand-Off (the “Lilly Additional Agreement”). Pursuant to the Lilly Additional Agreement, to the extent necessary to provide ViroPharma all the necessary rights under the TPSC, Lilly shall (i) assume certain obligations
in accordance with the terms of this Agreement, including subcontracting, sub-licensing, or subleasing to ViroPharma the benefits not received by ViroPharma in the TPSC Hand-Off and (ii) enforce for the benefit of ViroPharma, any and all rights of
Lilly against a third party. 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 Page 4 of 10 

 3. Effect of Assignment on Lilly. 
  
 (a) In the event that the TPSC Hand-Off takes the form of an assignment, then: 
  
 (i) With respect to the API Supply Agreement, Lilly shall
use commercially reasonable efforts to enter into an agreement directly with [***] to meet its requirements for finished Marketed Product in Canada. If Lilly is unable to enter into an agreement with [***] and until such time as Lilly shall have
obtained such an agreement or an alternative source of supply of API for Canada, ViroPharma will use commercially reasonable efforts to assist Lilly in meeting its requirements for API for a reasonable period of time. 
  
 (ii) With respect to the Finished Product Supply Agreement,
Lilly shall use commercially reasonable efforts to enter into an agreement directly with [***] to meet its requirements for finished Marketed Product in Canada. If Lilly is unable to enter into an agreement with [***] and until such time as Lilly
shall have obtained such an agreement or an alternative source of supply of finished Marketed Product for Canada, ViroPharma will use commercially reasonable efforts to assist Lilly in meeting its requirements for a reasonable period of time.

  
 4. Master Agreement with [***]. 
  
 With respect to the Master Agreement, in the event of assignment of the
Master Agreement to ViroPharma and prior to the date Lilly enters into any agreement directly with [***], the Parties agree to work together as follows: 
  
 (a) Section 2.2 Change In Specifications. ViroPharma will use its commercially reasonable efforts to include Lilly in negotiations with [***]
regarding implementation dates for changes in specifications, and ViroPharma will use its commercially reasonable efforts to give notice to Lilly of all changes and planned implementation dates. 
  
 (b) Section 4.1 Quarterly Forecast. Lilly shall provide to ViroPharma
Lilly’s forecast prior to any date in which ViroPharma is required to submit a forecast for Marketed Product to [***]. ViroPharma shall thereafter include such forecast in its forecast, subject to its requirements during the forecast period.

  
 (c) Section 8.1.3 Product Recalls. ViroPharma will use
its commercially reasonable efforts to consult with Lilly in connection with any recall. 
  
 (d) Section 8.1.4 Product Rework/Reprocessing. ViroPharma will use its commercially reasonable efforts to consult with Lilly in connection with product rework or reprocessing. 
  
 (e) Section 8.1.9 Regulatory Inspections. ViroPharma shall notify
Lilly of any governmental or regulatory inquiry, communication, audit or inspection of [***] facility and (Services and/or Manufacturing) processes directly relating to the Marketed Product. ViroPharma shall provide Lilly with copies of any written
communication from a governmental or regulatory agency relating to a Product as soon as reasonably practicable after its receipt. Lilly shall provide reasonable assistance to ViroPharma and [***] in responding to any such inquiry, communication, or
inspection relating to the Marketed Product. ViroPharma shall notify Lilly as soon as reasonably practicable if [***] plans to enter into a consent decree or an order being entered against [***] 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 Page 5 of 10 

 
involving [***] failure, or alleged failure to comply with cGMP. To the extent Lilly becomes aware of any such things, it will notify ViroPharma. 

 
 (f) Section 9.1 Supplier Relationship Team. ViroPharma shall
initiate formation of a team that will include one or more Lilly representatives (“Supplier Relationship Team”), which shall meet to address issues and oversee the relationship between Lilly and ViroPharma on the one hand, and [***]
on the other hand. Lilly shall discuss with ViroPharma and obtain ViroPharma’s approval prior to supporting [***] if [***] proposes projects that will improve the manufacturing process and reduce the costs for Marketed Product. A process for
reviewing, approving and financing such projects, which impact Marketed Product, shall be established and documented in the MRD. Lilly and ViroPharma shall establish a process for working together to comply with the requirements of the MRD and to
protect ViroPharma’s interest in the Territory and Lilly’s interest in the Canadian market. Lilly and ViroPharma shall share with [***] any cost savings to the manufacture of Marketed Product realized as a result of the work of the
Supplier Relationship Team and ViroPharma shall use its commercially reasonable efforts to require [***] to adjust accordingly the applicable Manufacturing Price. From time to time the Parties may, at their own expense, invite internal or external
consultants to advise the Supplier Relationship Team. Any and all such external consultants shall execute a confidentiality agreement in a form mutually acceptable to Lilly, ViroPharma and [***]. 
  
 (g) Section 16.1 Term. ViroPharma will give reasonable prior notice to
Lilly of any intention to terminate the Master Agreement with respect to Marketed Product in the Territory. 
  
 (h) Section 16.2 Material Breach. ViroPharma will give reasonable notice to Lilly of any written notification of Material Breach to [***]. In the
event of any such termination by ViroPharma, ViroPharma shall have no continuing obligations to Lilly with respect to the Master Agreement. 
  
 (i) Section 16.3 Termination for Insolvency. ViroPharma will give reasonable notice to Lilly of termination to [***] in the event [***] is or
becomes a Bankrupt Party, and following any such termination by ViroPharma, ViroPharma shall have no continuing obligations to Lilly with respect to the Master Agreement. 
  
 (j) Section 18 Force Majeure. ViroPharma will give reasonable notice to Lilly of circumstances constituting a Force
Majeure. 
  
 (k) Notice. Any notice to be provided pursuant
to this paragraph 4 shall be made as soon as reasonably practicable. 
  
 5.
Project Agreement. 
  
 With respect to the Project Agreement,
in the event of assignment of the Project Agreement to ViroPharma and prior to the date Lilly enters into any similar agreement directly with [***], the parties agree to work together as follows: 
  
 (a) Section 3, Paragraph 3 Equipment Purchase. ViroPharma shall
provide to Lilly any written notification that [***] provides to ViroPharma relating to [***] intended use of manufacturing equipment that will be utilized for the Product. 
  
 (b) Section 3, Paragraphs 4 and 5 Equipment Purchase. In the event any equipment is delivered to Lilly under the
Project Agreement following termination or non-renewal of the Project Agreement, Lilly shall ship such equipment to ViroPharma as soon as 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 Page 6 of 10 

 
reasonably possible (or direct [***] to ship to ViroPharma directly), provided, that, subject to paragraph (g) below, ViroPharma shall use commercially
reasonable efforts to meet or reasonably cause to be met Lilly’s requirements for Marketed Product for Canada for Lilly’s Affiliate or a Third Person to which marketing rights for Marketed Product have been transferred or licensed.

  
 (c) Section 5 Manufacturing Price. ViroPharma will
consult with Lilly as ViroPharma reasonably deems appropriate. 
  
 (d) Section 7 Term. ViroPharma will give notice to Lilly prior to any termination of the Project Agreement due to either expiration or breach of contract. 
  
 (e) Price Exhibit Manufacturing Price. ViroPharma shall use its commercially reasonable efforts to consult with Lilly
with respect to any discussions of modifications to the Manufacturing Price. 
  
 (f) Price Exhibit, Stability Costs. ViroPharma shall use its commercially reasonable efforts to consult with Lilly with respect to any discussions regarding non-routine stability requests. 
  
 (g) Non-Performance. Notwithstanding ViroPharma’s cooperation
obligations hereunder, ViroPharma shall have no liability for any failure or non-performance by [***] or any third party in connection with the supply of Marketed Product to Lilly for Canada, including, for purposes hereof, any shortages, delays, or
non-conformance in any supply of Marketed product. 
  
 (h)
Notice. Any notice to be provided pursuant to this paragraph 4 shall be made as soon as reasonably practicable. 
  
 6. Failure to reach agreement. 
  
 In the event that ViroPharma and Lilly are unable to agree on any matter that ViroPharma is required to address with [***] related to the manufacture and supply of
Marketed Product for the Territory, ViroPharma shall have the final decision, provided, however, that prior to any time at which Lilly enters into direct agreements with [***] to replace the Project Agreement and subject to the
provisions of Section 4(g) above, ViroPharma shall use commercially reasonable efforts to assist Lilly in obtaining Marketed Product from [***] with respect to Lilly’s requirements for product for Canada for Lilly’s Affiliate or a Third
Person to which marketing rights for product have been transferred or licensed; and provided, however, that ViroPharma shall have no obligation to allocate any of its Marketed Product for such purposes. Notwithstanding any provision in this
Agreement to the contrary, ViroPharma’s obligations under Sections 3, 4 and 5 hereof shall continue for a reasonable period of time to enable Lilly to enter into its own agreements, and shall only continue for such period of time that Lilly is
actively seeking to enter into such agreements. 
  
 7. Canada. 

 
 If ViroPharma intends to terminate any agreement with [***] or remove the equipment
utilized by [***] to manufacture Marketed Product for Canada, ViroPharma will (i) provide Lilly with twenty-four months advance written notice before taking such actions to allow Lilly a reasonable opportunity to obtain a source of supply for
Marketed Product for Canada, or (ii) agree on reasonable terms to supply, or cause a third party to agree 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 Page 7 of 10 

 
directly with Lilly to supply, Lilly with requirements for the Canadian market. Notwithstanding the foregoing in this Section 6, ViroPharma shall have no
obligations to Lilly for the supply of Marketed Product for Canada in the event Lilly enters into an agreement for supply with any third party. 
  
 8. Certain Payments. 
  
 Nothing in this Cooperation Agreement shall modify, amend or alter in any way the obligations agreed to by ViroPharma in Section 2.3(b) of the Manufacturing Agreement to be responsible for certain costs related to the
[***] agreements as described in that Section. 
  
 9. Notices. 

 
 Unless otherwise stated in this Agreement as to the method of delivery, all notices or
other communications required or permitted to be given hereunder will be in writing and will be deemed to have been duly given if delivered by hand, courier, facsimile or if mailed first class, postage prepaid, by registered or certified mail,
return receipt requested (such notices will be deemed to have been given on the date delivered in the case of hand delivery or delivery by courier, on the date set forth in the confirmation sheet in the case of facsimile delivery, and on the fifth
business day following the date of post mark in the case of delivery by mail) as follows: 
  
 If to Lilly, as follows: 
  
 Eli
Lilly and Company 
 Lilly Corporate Center 
 Indianapolis, Indiana 46285 
 Facsimile: (317) 433-3000 
 Attn: Executive Vice President, Pharmaceutical Products 
  
 With a copy to: 
  
 Eli Lilly and Company 
 Lilly Corporate Center

 Indianapolis, Indiana 46285 
 Facsimile: (317) 433-3000 
 Attn: General Counsel 
  
 If to ViroPharma, as follows: 
  
 ViroPharma Incorporated 
 397 Eagleview
Boulevard 
 Exton, PA 19341 
 Facsimile: (610) 458-2017 
 Attn: General Counsel 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 Page 8 of 10 

 With copies to: 
  
 Piper Rudnick LLP 
 6225 Smith Avenue

 Baltimore, MD 21209-3600 
 Facsimile: (410) 580-3001 
 Attn: Howard S. Schwartz, Esq. 
  
 or in any case to such other address or addresses as hereafter will be furnished in a written notice as provided in this Section 8 by any
Party hereto to the other Party. 
  
 10. Entire Agreement. 
  
 This Agreement, the Manufacturing Agreement and the Assignment Agreement, each of their
appendices, exhibits, schedules and certificates and all documents and certificates delivered in connection herewith and therewith constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior
agreements or understandings of the Parties relating thereto. 
  
 11.
Amendment. 
  
 This Agreement and the other agreements and documents
referenced herein contain the full understanding of the Parties with respect to the subject matter hereof and supersede all prior understandings and writings relating thereto. No waiver, alteration or modification of any of the provisions hereof
shall be binding unless made in writing and signed on behalf of the Parties by their respective officers thereunto duly authorized. 
  
 12. Counterparts. 
  
 This Agreement may be executed in any number of counterparts, each of which will be deemed an original but all of which together will constitute a single instrument. 
  
 13. No Joint Venture. 
  
 Nothing contained herein will be deemed to create any joint venture or partnership between the Parties hereto, and, except as is expressly
set forth herein, neither Party will have any right by virtue of this Agreement to bind the other Party in any manner whatsoever. 
  
 14. Severability. 
  
 If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws effective while this Agreement remains in effect, the legality, validity and enforceability of the
remaining provisions will not be affected thereby. 
  

 Page 9 of 10 

 15. Choice of Law. 
  
 This Agreement will be governed and construed in accordance with the laws of the State of Delaware, excluding its conflict of law rules. 
  
 16. Further Assurances. 
  
 Each Party hereby agrees, without further consideration, to execute and deliver such documents and take such other actions as the other
Party may reasonably request to carry out the provisions hereof, including without limitation, to implement the provisions of Section 2(d) above. 
  

			
	Eli Lilly & Company:
		
	Signed:	 	 /s/ John C. Lechleiter

	
	 Name: John C. Lechleiter

	
	 Title: Executive Vice President

	
	 Date: October 18, 2004

	
	ViroPharma Incorporated:
		
	Signed:	 	 /s/ Michel de Rosen

	
	 Name: Michel de Rosen

	
	 Title: Chief Executive Officer

	
	 Date: October 18, 2004

  

  
 EXHIBIT A 
  
 [***] 
  
 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]